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Breast cancer is the most common form of malignancy in Scottish women and its
incidence appears to be increasing with time. It is therefore important to identify
factors associated with risk and outcome. In this thesis two separate but interrelated
social aspects of the natural history of breast cancer have been examined - (i) the
location of the primary tumour within the breast in two groups of patients diagnosed
40 years apart and (ii) the effects of socioeconomic status on prognostic factors and
outcome of patients with breast cancer. Whilst breast cancer occurs equally in right
and left breasts, tumours most commonly affect the upper outer quadrant (UOQ) of
the breast. However, there is no information as to whether the incidence has
changed over time. To address this, the present study investigated two groups of
women diagnosed with breast cancer in the south-east of Scotland between either
1957-1959 or 1997-1999 (ie 40years apart). The earlier group represent 1158 of 1207
women referred to radiation oncologists in the region and the later group comprised
1477 of about 1600 women referred to the Edinburgh Breast Unit. Whilst the age,
menopausal status and laterality of the patients were similar in both groups, the
tumour size and tumour location within the breast were significantly different in the
two groups. Thus, there was significant reduction in T stage with year of diagnosis
(p<0.0001), the incidence of Tl, T2, and T3/4 being 15.6%, 51.9% and 25.6% in the
earlier cohort compared with 49.3%, 36.8% and 13.7% in the later group. The overall
distribution within the breast was significantly different by chi-squared analysis
(p<0.0001). In terms of individual quadrants 469 of 1158 (40.5%) tumours were
located in the upper outer quadrant (UOQ), whereas in the more recent cohort it was
788 of 1477 (53.4%), this increase in proportion being statistically significant
(p<0.0001). Occurrence in the lower outer quadrant (LOQ) also significantly
increased (p<0.028) but was significantly reduced in the upper inner quadrant (UIQ)
and centrally (both p<0.0001). Analysing data on location for each T stage separately
showed that the increased incidence in the UOQ with time was apparent for each
subgroup. The increased incidence in UOQ tumours over time is therefore not a
simple reflection of decreased size between the two time groups. The underlying
reason(s) for this change in distribution with time requires further study. Affluent
women have a higher incidence of breast cancer than socially deprived women but
may have a better outcome from the disease. The aims of the study in this thesis
were to (i) quantify and investigate differences in survival and recurrence from
breast cancer between women differing in socioeconomic status from the south-east
of Scotland and (ii) define the contribution of underlying factors to this variation. To
do this, 502 patients with non-metastatic invasive breast cancer referred to the
Edinburgh Breast Unit between 1985 and 1993 were stratified according to Carstairs
Index. This subdivides individuals into deprivation categories (DEPCAT) according
to postal address. The most affluent have DEPCAT 1 and 2 and the most deprived
areas are DEPCAT 6 and 7. The majority of women fell into DETCAT status 3 and 4
(25.1 and 27.1 respectively) whilst 10.4 and 16.3 % were placed in the most affluent
DEPCAT 1 and 2 groups and 15.1, 2.6 and 3.4% in the most deprived DEPCAT 5, 6
and 7 groups respectively. To increase numbers in small groups and have
approximately equal numbers, analyses were also performed combining DEPCAT
scoresl and 2 to provide Zone A and DEPCAT scores 5,6 and 7 to provide Zone D
(DEPCAT 3 was zone B and DEPCAT 4 was zone C). In terms of recurrence, there
were trends for more affluent DEPCAT categories to have a better outcome but these
did not reach statistical significance. However women from the most affluent zone
had significantly better DFI than the socially deprived (p= 0.0 by Kaplan Meier).More
affluent women (on the basis of either DEPCAT groups or zones) had a better
survival compared to the most deprived. Based on single follow up time of 5 years,
survival difference were statistically significant by chi-square analysis (p=0.026 for
DEPCAT and 0.011 for zones). Furthermore, using the total follow-up until 2002,
Kaplan Meier analysis of SES zones showed that affluent women had a significantly
better survival (p=0.02). SES was not related to menopausal status or established
prognostic factors such as lymph node status, tumour size and ER status, although
lymph node status and tumour size were highly significantly associated with patient
survival (p<0.0001 and 0.0006 respectively by Kaplan Meier). Given that these
established factors do not relate to SES and that the patients were treated by defined
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protocols irrespective of SES, the factors underlying the differences in outcome
between affluent and deprived women in Edinburgh remain undefined. Further
research is required to identify other reasons for poorer outcomes in deprived
women, with a view to reducing these survival differences. These 2 studies provide




1.1 General Statistics Associated with Breast Cancer
1.1.1 Incidence
Worldwide, more than a million women are diagnosed with breast cancer every
year, accounting for a tenth of all new cancers and 23% of all female cancer cases [1].
Breast cancer is the commonest malignancy in females in Scotland; one woman in 15
can be expected to be affected with the disease by the age of 74. This is equivalent to
a 6.6% lifetime risk of the disease [2]. During the 1980s, breast cancer accounted for
24% of all malignancy neoplasms in Scottish women, ie an average 2,660 new cases
per year resulting in 1,250 breast cancer deaths per year.
There is a clear relationship between age and incidence. Overall the incidence of
breast cancer rises with age. Thus, very few women under the age of 25 years
develop breast cancer. Thereafter the incidence of the disease increases but plateaus
at age 45-50 (which probably represents an effect of the menopause). Amongst
young women in Scotland, in the decade to 1990, only 129 cases occurred under the
age of 30 and 3,252 cases of breast cancer occurred in women under 45 years of age,
this representing 8.1% of the total. Over half of the cases under 45 were in the age
group 40-44 years [2]. The vast majority of breast cancers occur in older
postmenopausal women.
Incidence increases more rapidly during the fourth decade of life and continues to
increase thereafter, but more slowly in the fifth, sixth and seventh decades (after the
menopause) [3]. In the USA, 75% of new diagnoses of breast cancer are in women
aged 50 years or older. The cumulative incidence of breast cancer among women in
Europe and North America is about 2.7% by age 55, about 5.0% by age 65, and about
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7.7% by age 75 [4] and the lifetime risk of a diagnosis of breast cancer is
approximately 12.5%.
The incidence of and mortality from breast cancer both vary about 5-fold between
populations worldwide. Rates tend to be higher in more developed countries as
compared with less developed countries, most notably in Africa and Asia [1].
The reason for this variation seems to be mainly environmental. In studies of
migrants who move from low-risk to high-risk countries it is shown that rates
increase and eventually become similar to those amongst the high-risk populations
[5-7].
For example, breast cancer rates are about 4-7 times higher in the United States than
in China or Japan. However, risk of breast cancer in Chinese, Japanese or Filipino
migrants to the United States increases over several generations and approaches that
among indigenous US Whites [6, 7],
Interestingly, the differences in the age-specific incidence of breast cancer are greatest
after about age 50. For example, at the ages of 45 to 49, the incidence rates in the
United States and Japan are 195 and 55 per 100,000 respectively but, after age 50,
incidence in the United States continues to increase while in Japan it remains
relatively constant. As a consequence, at 64 to 69 years, the rates for the United
States and Japan are 404 and 53 per 100,000.
In Britain the age-standardised incidence of breast cancer per 100,000 women
increased from 75 in 1979 to 116 in 2002. Over the twenty year period 1983-2002 the
incidence rate increased by 45% [8-10], The historically low rates in Eastern Europe
and the Far East have begun to rise rapidly [11-13].
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1.1.2 Mortality
Mortality from breast cancer among women varies significantly from country to
country. The adjusted death rate per 100,000 women (1983-1987) was approximately
29 for England and Wales, 23 for US-white, 15 for Spain and 6 for Japan. Survival
figures for England show that an average of 77% of women diagnosed with breast
cancer in 1996 to 1999 were alive five years later [1,14],
Although the breast cancer incidence rate has been increasing world-wide since 1950,
mortality rates have levelled off or begun to decline recently. Most notably, the
countries that have shown a downturn in mortality are generally those with the
highest rates, whereas the countries with the lowest mortality rate tend to be the ones
in which the mortality is increasing [15].
Increasing breast cancer survival, observed in most western countries, is not easily
interpreted. It could be due to better treatment, more effective treatment due to
earlier diagnosis or simply lead-time bias. Increased diagnostic activity (eg
screening) can inflate both incidence and survival. The following patterns emerged
(i) increasing survival with increasing incidence and declining or stable mortality
(Sweden, Finland), (ii) slight survival increase, marked incidence increase and slight
mortality decrease (Denmark, the Netherlands and France), (iii) increasing survival,
marked decrease in mortality and tendency to incidence stabilization (UK), (iv)
marked survival increase, steady or decreasing mortality and moderate increases in
incidence (Spain, Italy), (v) stable survival, increasing incidence and mortality
(Estonia). In most countries survival increased, indicating a real advantage for
patients when accompanied by decreasing or stable mortality and attributable to
improved cancer care (Sweden, UK, France, Italy and Spain). In Finland (with high
survival), the Netherlands and Denmark increasing mortality and incidence indicate
increasing breast cancer risk, probably related to lifestyle factors. In Estonia, low and
stable survival in the context of increasing incidence and mortality suggests
inadequate care [14],
3
1.2 Risk factors in breast cancer
In addition to age and country of residence as reviewed in 1.1.1, there are other
factors which influence risk of breast cancer [5]. Many of these risk factors have a
strong endocrine link such as menarche, menopause, childbearing, breastfeeding,
obesity and anthropometric variables, levels of endogenous hormones and use of
exogenous hormones (oral contraceptives and hormone replacement therapy).
1.2.1 Menarche
For each 1-year delay in menarche, the risk decreases by around 5% [16]. Although
age at menarche is related to breast cancer risk at all ages, the effect may be stronger
in younger (premenopausal) women. Relative risk for premenopausal breast cancer
is reduced by an estimated 7% for each year that menarche is delayed after age 12
years, and by 3% for postmenopausal breast cancer [17-19], Low risk countries such
as China have a later average age at menarche (16-17 years).
1.2.2 Menopause
Menopause, either natural or induced, reduces risk of breast cancer and risk
reduction is greater the earlier that menopause occurs. For example, incidence of
breast cancer is about halved if the menopause occurs before age 45 years as
compared to after age 55 years. Risk increases by about 3% for each year older at
menopause [4].
The menopause is probably responsible for the slowing in the rate of increase in
breast cancer incidence with age that occurs at around age 50. Thus, premenopausal
women are at higher risk of breast cancer than postmenopausal women of the same
age, and perimenopausal women are at intermediate risk [4,17].
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The effects that early menarche and late menopause have in increasing risk suggest
that the number of menstrual cycles that a woman has may be an important
determinant of risk, and that risk may be reduced in those with prolonged
amenorrhea [16, 17].
1.2.3 Childbearing
That parity reduces the risk of breast cancer has long been recognized. In the 18th
century Bernado Ramazzini reported the high rate of breast cancer in nuns compared
with married women and speculated that this might be associated with their lack of
children. Subsequently, it was shown that women who had at least one full-term
pregnancy compared with nulliparous women on average have around a 25%
reduction in breast cancer risk [20]. In a meta-analysis nulliparity was associated
with a 30% increase in risk compared with parous women [21].
Some evidence suggests that the earlier the full-term pregnancy, the earlier the
period of decreased susceptibility of breast tissue changes begins [17]. The relative
risk of developing breast cancer increases by 3% for each year of delay [22], The age
at first full-term pregnancy affects risk of breast cancer independently of the total
number of pregnancies; protection is greater the younger the age at first birth [17]. In
a meta-analysis of studies from Nordic countries, women who had their first birth
when younger than 20 years had a 30% lower risk of breast cancer than those with a
first birth after the age of 35 [21].
Furthermore, increasing protection is seen with increasing numbers of full-term
pregnancies, such that women with five or more children have about half the risk of
nulliparous women [21]. In the absence of breast feeding there is a reduction in risk
of 7% for each birth after the first [22].
However, the effect of childbearing is complex. Thus it may have a dual effect on
risk of breast cancer; incidence is increased in the period immediately after a birth,
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but this excess risk gradually diminishes and, as discussed above, in the longer term
the effect of a birth is to protect against the disease [20]. To complicate matters, a first
pregnancy very late in reproductive life (after age 35 years) may increase risk beyond
that in nulliparous women.
1.2.4 Breastfeeding
The effect of breastfeeding on risk of breast cancer is controversial, probably because
the effect is small. However studies in less developed countries, where the total
duration of breastfeeding can be very long, have reported substantial protective
effects [23],
Protection has also been seen in some, but not all, studies in more developed
countries. For example, the US Cancer and Steroid Hormone Study examined the
relation between breastfeeding and breast cancer in over 4,500 women with the
disease and found that women who had breastfed for a total of 25 months or more
had a 33% lower risk of breast cancer than those who had never breastfed, with
adjustment for parity and age at first full-term pregnancy [20]. The relative risk of
breast cancer decreased by 4.3% (95% CI 2.9-5.8; p<0.0001) for every 12 months of
breastfeeding in addition to a decrease of 7.0% (5.0-9.0; p<0.0001) for each birth. The
size of the decline in the relative risk of breast cancer associated with breastfeeding
did not differ significantly for women in developed and developing countries, and
did not vary significantly by age, menopausal status, ethnic origin, the number of
births a woman had, her age when her first child was born or any of nine other
personal characteristics examined. The lack of or short lifetime duration of
breastfeeding typical of women in developed countries makes a major contribution
to the high incidence of breast cancer in these countries [22].
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1.2.5 Obesity and anthropometric variables
In postmenopausal women, obesity increases the risk of breast cancer; risk is about
50% higher in obese women (body-mass index >30 kg/m2) than in lean women (body
mass index 20 kg/m2). This association is not observed in premenopausal women
among whom some, but not all, studies have observed that risk is slightly lower in
obese women than in women of normal weight [24-26],
Adult height shows a weak positive association with breast cancer risk [27, 28].
Average height is substantially greater in populations with high rates of breast
cancer than in populations with low rates. Within populations, a 10 cm greater
height is typically associated with an increase in risk of about 10% [29] and there was
an approximate increase in relative risk of 7% for each additional 5 cm in height for
postmenopausal women and 2% for premenopausal women [28],
The underlying mechanism for the association between height and breast cancer risk
is unclear, and it is likely that height may be a marker for other exposures that
influence breast cancer risk [27],
1.2.6 Endogenous Hormones
There are only a few prospective studies on endogenous sex hormone levels and
breast cancer risk [30]. The risk for breast cancer increased statistically significantly
with increasing concentrations of all sex hormones examined: total oestradiol, free
oestradiol, non-sex hormone-binding globulin (SHBG)-bound oestradiol (which
comprises free and albumin-bound oestradiol), oestrone, oestrone sulfate,
androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate and
testosterone.
Amongst the sex hormones, oestrogens have been most consistently linked with risk
of breast cancer. Associations have been proposed with total lifetime exposure to
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oestradiol, exposure to bioavailable oestradiol, exposure to oestrogen plus
progesterone, or exposure to oestradiol at times of progesterone insufficiency that
may exist during menarche and the perimenopausal period [31]. Low serum
oestradiol concentrations have been found in premenopausal populations at low risk
of breast cancer [32], In postmenopausal women, several prospective nested case-
control studies have linked raised oestrogen concentrations after the menopause
with subsequent breast cancer development [4, 33, 34], Studies of postmenopausal
women in populations with different risks of breast cancer have generally shown
that women from the population with the higher risk country have an overall mean
level of serum oestradiol about 20 per cent higher than women from low risk
countries. These comparisons have included American whites and Asian migrants to
Hawaii, women in Britain and China, and women in the United States and Japan.
The factors responsible for these differences in oestradiol levels are not yet known,
but they may be due to differences in body fat and in diet. The effect of obesity in
increasing risk in postmenopausal women may be due to increased blood levels of
oestradiol produced from androstenedione in adipocytes.
1.2.7 Exogenous sex hormones
Oral contraceptives
Oral contraceptives were introduced in the early 1960s, and only relatively young
women have had the opportunity to use them from the start of their reproductive
lives. Substantial numbers of women with prolonged exposure to oral
contraceptives early in life have only recently entered the age group where breast
cancer is common, and the full impact of long-term oral contraceptive use on breast
cancer risk may not yet have been seen. It is also possible that breast tissue still
undergoing development in the young may be more susceptible to the effects of
hormones and at greater risk of developing cancer after exposure. The literature
suggests that early exposure to oral contraceptives, either by use in adolescence, or
use before age 25 years, or prolonged use before first pregnancy, may increase risk.
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However, contradictory evidence exists in each of these areas. The risk of breast
cancer is increased by around 25% in current users of combined oral contraceptives,
but the excess risk falls after cessation of use, such that 10 or more years after use
stops, no significant increase in risk is evident. The effect on risk of breast cancer
does not vary with the type of oestrogen or progestogen used. Although data on
progestogen-only oral contraceptives are limited, their effects seem to be broadly
similar to those of combined preparations [34],
Use of combined oral contraceptives is associated with a larger excess of localised
cancers than those that have spread beyond the breast [34], This finding has raised
the possibility that the increased risk of breast cancer in recent users of oral
contraceptives may be partly due to increased surveillance.
Hormone replacement therapy
Increasing numbers of women in their 50s and 60s are using hormone replacement
therapy to alleviate menopausal symptoms. The effect of long term use of these
agents in women aged over 50 on the breast is only now becoming apparent.
Worldwide data on the relationship of hormone replacement therapy (HRT) to breast
cancer risk have been analysed by the Collaborative Group on Hormonal Factors in
Breast Cancer [34], HRT increases risk of breast cancer in current and recent users
(within five years). Risk increases by about 2% for every year of use. The magnitude
of the effect of HRT on risk of breast cancer is similar in magnitude to that of a
delayed menopause. Between age 50 and 70 cumulative incidence is 45 per 1,000 in
non-users, and is increased by 2 in users for 5 years, and by 6 in users for 10 years.
The effect of HRT on risk appears to be greater among women of lower body weight.
There appears to be no increased risk of breast cancer among women who stopped
using HRT more than 5 years previously, regardless of the length of time that they
had taken HRT [34], The risk of having breast cancer diagnosed is increased in
women using HRT and increases with increasing duration of use. This effect is
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reduced after cessation of use of HRT and has largely, if not wholly, disappeared
after about 5 years [35],
Studies have reported significantly higher levels of risk of breast cancer in women
taking combined oestrogen and progestogen preparations compared with women
taking oestrogen alone [36].
Xenoestrogens
Some compounds that are environmental contaminants have weak oestrogenic
properties. These compounds include polychlorinated biphenols (PCBS), and the
pesticide DDT and its metabolites. These and other similar compounds are
persistent environmental pollutants that have been found in fish, wildlife and
humans. Most epidemiological studies have not found evidence to support the
hypothesis that exposure to PCBS and DDT increases risk of breast cancer [37].
1.2.8 Family history
The evidence for genetic predisposition to breast cancer derives originally from
observations of cancer clustering in families and cancer risk increasing in individuals
with some genetically determined syndromes. Individuals with a family history of
breast cancer are at increased risk of developing the disease. The magnitude of the
increase in risk in an individual is influenced by the number of relatives affected, by
the age at onset in those affected and by their relationship to the individual. The risk
of the cancer is approximately doubled in first-degree relatives (mothers, sisters,
daughters) of affected patients [38, 39]. With affected second-degree relatives
(grandmothers, aunts, grand-daughters), there is a lesser increase in risk. Risk to
relatives is greater when there is early onset or bilateral disease in those affected. At
least some of the increased risk associated with a family history of breast cancer is
due to the inheritance of genes that predispose to the disease. Environmental and
lifestyle factors rather than inherited genetic factors account for most cases of breast
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cancer. Less than 10% of women in the general population have a family history of
breast cancer [40]. Most women with the disease do not have a family history of it,
and most women with affected relatives never develop breast cancer.
About 5-10% of cases of breast cancer are due to germline mutations in cancer -
susceptibility genes showing autosomal dominant inheritance. Two genes, BRCA1
and BRCA2, have been isolated and shown to be the cause of up to 80% of large
breast cancer kindreds [41].
Despite the obvious importance of mutations in BRCA1 and 2 in the aetiology of
breast cancer, mutations in these genes are present in only a small proportion of
subjects with breast cancer.
1.2.9 Dietary variables
International differences in the incidence of breast cancer, and the results of animal
experiments, suggest that diet may play an important role in the aetiology of breast
cancer [42], Although there are several components of the diet for which there is
some evidence of an influence on the risk of breast cancer, the strength of the
evidence varies and in some areas it is the subject of considerable controversy. The
available evidence suggests that increased intake of energy, of dietary fat, meat and
alcohol may all increase risk [43, 44] and that increased intake of fibre, fruits and
vegetables, antioxidant vitamins and phytoestrogens may all reduce risk [5].
1.2.10 Physical activity
A recent report from the International Agency for Research on Cancer concluded that
physical activity has a preventive effect on breast cancer [25]. This may be an
indirect effect with exercise lowering BMI, or a direct effect on hormonal and growth
factor levels. The magnitude of this effect varies between studies; a typical result is a
11
30-40% reduction in the risk of breast cancer with a few hours per week of vigorous
activity versus none [45],
Physical activity is associated with leanness, later onset of menarche and with a
greater frequency of amenorrhea, all factors associated with a reduced risk of breast
cancer. Two of four cohort studies and two case-control studies have shown that
physical activity is associated with a reduced risk of breast cancer [25, 45].
Several studies have reported that moderate physical activity is associated with a
lower risk of breast cancer. The data are not entirely consistent, although they are
somewhat stronger for premenopausal women than for postmenopausal women
[45].
1.2.11 Exposure to Radiation
Epidemiological studies in humans show that exposure to radiation increases risk of
breast cancer. The evidence comes from the follow-up of individuals exposed to
radiation in a variety of circumstances including atomic bomb explosions in Japan,
fluoroscopic chest radiography for tuberculosis, and therapeutic radiation for benign
and malignant conditions. Studies in these different populations of subjects suggest
that risk of breast cancer increases between 5 and 10 cases per 10,000 for every G ray
of exposure. The effect of exposure to radiation on risk of breast cancer is strongly
influenced by age at the time of exposure. Risk is greatest among women aged less
than 20 at exposure, and least among those aged more than 40 years. Exposure in
early childhood may also increase risk.
A recent study estimated that exposure to diagnostic x-rays may be responsible for
29 cases per year of female breast cancer before the age of 75 in the UK, an
attributable risk of 0.1% [46]. Overall, 0.6% of the cumulative risk of cancer to age 75
might be radiation-induced in the UK - approximately 700 cases of cancer each year.
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1.2.12 Previous Benign Disease
The majority of women who undergo breast biopsy are not at increased risk of breast
cancer. The histologically heterogeneous group of 'benign breast diseases' is often
divided into non-proliferative lesions and proliferative lesions without or with
atypia. Non-proliferative lesions are generally associated with little or no increase in
risk of breast cancer [47], Proliferative lesions without atypia confer an increase in
risk of about twofold and atypical hyperplasias an increase of at least four-fold
compared with women without benign breast disease.
1.2.13 Radiographical breast density
The radiographic appearance, or mammographic pattern, of the female breast varies
between individuals because of differences in the relative amounts of fat, connective
and epithelial tissue [48]. Mammographic pattern is associated with age and
menopausal status; the breasts of young, premenopausal women are generally of
greater radiodensity than those of older, postmenopausal women [49],
At least 13 cohort studies, or case-control studies nested in cohorts, have
demonstrated that radiologically dense breasts have an increased risk of breast
cancer. The risk of breast cancer in women with extensive breast tissue visible on a
mammogram have a risk of breast cancer that is 1.8 to 6.0 times that of women of the
same age with little or no density [50], The decline in breast density with age, and
the significant increase after initiation of oestrogen-replacement therapy, suggest that
the tissue changes are reversible and under hormonal control [51].
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1.3 Natural History of Breast Cancer
Breast cancer usually starts by an abnormal and uncontrolled growth of cells lining
the lobule terminal duct unit [52],
The most common type of non-invasive breast cancer is ductal carcinoma in situ
(DCIS). If not treated this may develop into an invasive form of breast cancer. The
most common type of invasive breast cancer is called invasive ductal carcinoma
(IDC). Around three in four people with breast cancer have this type [53].
The staging of breast cancer involves clinical, pathological and radiological data, a
commonly used classification system is the TNM (Tumour, Nodes, Metastases)
system which stage a tumour according to the size and extent of local spread of the
tumour, the presence of lymph node metastases, and the presence of distance
metastases (usually to the liver, bone, lung and brain).
In the UK the majority of breast cancer cases are early breast cancers, diagnosed
usually at TNM staging T1 and T2 [54],
Surgical concept assumes that cancers grow and spread in an orderly manner, from
primary cancer to regional lymph nodes and finally to vital organs. When breast
cancer spreads beyond the breast, it is said to be "metastatic", meaning that it has
travelled from the breast to another part of the body. Cancer cells can travel through
either the lymphatic system or the blood vessels.
There are two types of metastatic breast cancer. When the cancer cells travel from
the breast to the under arm (axillary) lymph nodes, it is still considered an "early" or
potentially curable breast cancer. With proper surgery and systemic treatments,
there is still a good chance that all cancer can be removed from the body.
If the cancer has travelled past the lymph nodes to another part of the body, a
woman is said to have "distant metastasis". The most common places that breast
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cancer spreads to are the bones, the liver and the lungs. Many treatments are
available for breast cancer that has spread to other parts of the body, but
unfortunately once cancer has escaped from the breast and underarm lymph nodes,
it is no longer curable [53, 55].
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1.4 Treatment
Treatment of breast cancer depends upon a variety of factors such as menopausal
status of the patient, type of breast cancer, tumour size, histological grade and stage
(early breast cancer locally advanced or distant metastatic) and co-morbidity. The
main treatment modalities for breast cancer are surgery, radiotherapy, hormone
therapy, chemotherapy and biological response modifiers.
1.4.1 Early breast cancer
Because the disease is apparently restricted to the breast, the primary treatment for
early breast cancer (EBC) is breast surgery plus local radiotherapy. In high-risk
women consideration needs to be given to some form of adjuvant systemic therapy
for occult micrometastases.
Breast-conserving surgery and radiation
Clinical trials have demonstrated that women with early-stage breast cancer who
receive breast-conserving surgery followed by radiation have survival outcomes
similar to those of women who receive a mastectomy [56]. A 1990 NIH Consensus
Development Panel concluded that "breast conservation treatment (breast-conserving
surgery followed by radiation therapy) is an appropriate method of primary therapy
for the majority of women with stage I and II breast cancer and is preferable because
it provides survival equivalent to total mastectomy and axillary dissection while
preserving the breast" [56]. Breast-conserving surgery followed by radiation therapy
is associated with a lower rate of local recurrence than breast-conserving surgery
alone [56, 57].
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Adjuvant systemic therapy in high risk, lymph node positive patients
Chemotherapy may be given to high risk patients (based on patient's age, the size of
the tumour, grade of the tumour and presence or absence of lymph node
involvement). When used as adjuvant therapy after breast conservation therapy or
mastectomy, chemotherapy reduces the risk of breast cancer recurrence, either as an
adjuvant or neoadjuvant therapy. Meta-analyses have shown that the benefits of
chemotherapy are greater in premenopausal women as compared with their
postmenopausal counterparts. Clinical research studies over the last 30 years have
determined which combinations of chemotherapy drugs are most effective.
However, the "best" combination may not have yet been discovered, so there
continue to be clinical research studies comparing one of today's most effective
treatments against something that may be better. However, the most commonly
used combinations are:
■ Cyclophosphamide (Cytoxan), methotrexate (Amethopterin, Mexate, Folex),
and fluorouracil (Fluorouracil, 5-FU, Adrucil) [abbreviated CMF]
■ Cyclophosphamide, doxorubicin (Adriamycin), and fluorouracil [abbreviated
CAF]
• Doxorubicin (Adriamycin) and cyclophosphamide [abbreviated AC]
■ Doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel
(Taxol) or docetaxel (Taxotere) [abbreviated AC —>T] or docetaxel concurrent
with AC [abbreviated TAC]
■ Doxorubicin (Adriamycin), followed by CMF
■ Cyclophosphamide, epirubicin (Ellence), and fluorouracil [abbreviated CEF]
with or without docetaxel
■ Cyclophosphamide and Docetaxel (TC)
■ Gemcitabine (Gemzar) and paclitaxel (Taxol) [abbreviated GT]
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Adjuvant hormonal therapy
In patients with oestrogen receptor-positive tumours, hormone therapy has been
shown to produce significant clinical benefits including overall survival [35]. In
premenopausal women consideration can be given to oophorectomy and LHRH
agonists, whereas in postmenopausalwomen until recently tamoxifen was
recommended [58] although aromatase inhibitors are increasingly used (see section
below).
1.4.2 Advanced breast cancer
When the tumour has progressed beyond the breast, it is essential to treat
disseminated disease. Locally advanced disease may be treated with radiotherapy
and/or neoadjuvant systemic therapy followed by local surgery [59]; but distant
metastatic disease invariably requires systemic therapy (either chemotherapy or
endocrine therapy).
Endocrine therapy
Oestrogen sensitive cancers make up around 75% of breast cancers in
postmenopausal women and around 50-60% in premenopausal women.
Measurement of oestrogen receptors is the single best parameter by which to identify
hormone sensitive tumours.
Current guidelines recommend that patients with ER-positive tumours should have
hormone therapy, whereas those with ER-negative tumours should have
chemotherapy. Whilst tamoxifen until recently has been the first choice drug, the
efficacy of third-generation aromatase inhibitors has been clearly proven in trials in
metastatic breast cancer [60], In premenopausal women LHRH agonists either alone




Systemic chemotherapy for breast cancer may produce clinical benefits in advanced
breast cancer. Overall response rates to chemotherapy are about 40-60% with a
median time to relapse of 6-10 months. Analogues of the most potent drug
(Doxorubicin) are most commonly used. The main reason for considering them is a
greater safety margin [61].
Some other chemotherapy drugs used for treating women with breast cancer include
carboplatin (Paraplatin), cisplatin (Platinol), vinorelbine (Navelbine), capecitabine
(Xeloda), pegylated liposomal doxorubicin (Doxil), and albumin-bound paclitaxel
(Abraxane).
Biological therapy
One such drug, trastuzumab (Herceptin), targets breast cancer cells that have a
protein called HER2 on their surface [62], Trastuzumab is currently licensed for the
treatment of women with advanced breast cancer who have a particular genetic flaw
that produces the protein HER2. It is also being used in some women with early-
stage breast cancer as part of clinical trials and has shown promising results [63].
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1.5 Prognosis
Prognosis of breast cancer is variable and even women with the same stage of disease
despite treatment/no treatment may have different outcomes, hence the need for
prognostic factors to spare those who have indolent disease the side-effects of
treatment but to ensure those with aggressive disease are not undertreated.
Prognosis prediction for patients with breast cancer is currently based on
histopathological typing and oestrogen receptor positivity, although patients with
same staging may have disparate outcomes, which may indicate that the prognosis is
multifactorial and no individual factor is definitive. Prognostic factors can be
broadly classified into two groups: chronological factors, which are indicators of how
long the cancer has been present and relate to stage of disease at presentation, and




The pathological size of a tumour correlates directly with survival - patients with
smaller tumours have a better survival rate than those with large tumours [64-68],
Status of axillary lymph nodes
Axillary lymph node status has repeatedly been shown to be the single most
important predictor of disease-free survival and overall survival in breast cancer.
Survival of patients with breast cancer according to involvement of axillary lymph
nodes is 64.9% for negative axillary lymph nodes and 45.9% for positive axillary
lymph nodes, at 10 years for all patients.
20
Only 20-30% of node-negative patients will develop recurrence within 10 years,
compared with about 70% of patients with axillary nodal involvement. The absolute
number of involved nodes is also of prognostic importance. Patients with 4 or more
involved nodes have a worse prognosis than those with fewer than 4 involved nodes
[69, 70].
Metastases
Patients in whom cancer has spread beyond the axillary or internalmammary nodes
(Ml or stage IV disease) have a much worse survival rate than patients whose disease
is apparently localized. For example, patients with Stage IV disease only have an
18% chance of surviving to 5 years compared with 84% with Stage I, 71% with Stage
II (Stage III has an intermediary survival of 48%) [71]. There are differences in
survival between patients depending on the site of the metastatic disease, with
patients who have supraclavicular involvement as their only site of metastases
having a much better survival rate than patients with metastases at other sites.
Age at diagnosis
Recent evidence suggests that age at diagnosis may also be a risk factor: younger





Many of the so called special types of invasive breast carcinoma (invasive tubular,
cribriform, mucinous, papillary and microinvasive) are associated with a much better
prognosis than cancers ofno special type. Histological type is one of the best
predictors of long term survival [72].
Histological grade
The three characteristics of tubular formation, nuclear pleomorphism and mitotic
frequency are assessed in a semiquantitative manner to give three histological grades
(I, II, and III) which correlate directly with survival. Survival of patients according to
histological grade of tumour is 85% for grade I, 60% for grade II and 40% for grade III
[73]. Histologic grade is an important determinant of prognosis that also allows risk
stratification within a given tumour stage [74-77].
Lymphatic or vascular invasion
Tumour cells can be identified in lymphatic and blood vessels in up to a quarter of all
patients with breast cancer. Their presence is associated with at least a doubling of
the rate of local recurrence after wide local excision or mastectomy and patients with
this feature are at high risk of short term systemic relapse.
Peritumoural vascular invasion (either blood vessel or lymphatic channel) is
predictive of local failure and reduced overall survival [78]. Although some studies
have found no correlation with clinical outcome, this may be a reflection of
differences in distinguishing true vascular space invasion from retraction artifact.
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Markers of proliferation
Patients with tumours that have a high rate of proliferation have an increased rate of
local recurrence and a worse survival rate than patients whose tumours proliferate
slowly. Several methods to measure proliferation have been reported, including
measurement of the fraction of cells in the S phase of the cell cycle, the use of
monoclonal antibodies such as Ki67, KiSl, and MIB-1, and identification of
proliferating cells by the use of tracers such as bromodeoxyuridine. These
measurements may be used to stratify patients into good and poor prognostic groups
[79-83]. The monoclonal antibody MIB-1 recognizes Ki-67 but can be used in
formalin-fixed, paraffin-embedded tissue sections. Several studies have suggested
that MIB-1 may have greater predictive value than anti-Ki-67 [82],
Hormone and growth factor receptors
The presence of oestrogen receptors in a breast cancer predicts response to hormonal
manipulation. This appears to be of some value in predicting early outcome after
treatment but is of limited value in predicting long term survival. Progesterone
receptors can be identified in some breast cancers. Their presence depends on an
intact oestrogen receptor pathway, but it is not clear that they are of more value than
oestrogen receptors in predicting prognosis or response to hormonal treatment. One
study showed women with oestrogen receptors in their tumours survived
significantly longer than those without receptors; this was true for both
premenopausal and postmenopausal women and also when the patients were
subdivided into those with and without axillary metastases. Patients with axillary
metastases and no oestrogen receptors in their tumours had the worst prognosis,
while women with axillary metastases and oestrogen receptors had a death rate
similar to that of women with no axillary metastases and no receptors. The
oestrogen-receptor (ER) content of the primary tumour was measured in 133
postmenopausal women with operable breast cancer. Fifty nine (59%) were positive
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for oestrogen and 54 (41%) negative. Curves of life survival show that women with
ER-positive tumours live longer than those with ER-negative tumours [84-86],
The presence of epidermal growth factor receptors within the membrane of breast
cancer cells is inversely correlated with the presence of oestrogen receptors [87-90]
and is associated with a diminished period free of relapse and reduced overall
survival [91].
However, studies of the prognostic significance of EGFR expression have provided
mixed results, with only some studies showing a correlation between EGFR and
poorer disease-free survival [89, 90, 92, 93].
c-erbB2 (Her2-neu)
c-erbB2 altered breast cancer is associated with high histologic grade and reduced
survival [94-97], c-erbB2 is overexpressed in 15-30% of invasive cancers [98, 99] and
in up to 80% of non-invasive cancers, and its product is homologous with the
epidermal growth factor receptor. Patientswith lymph node involvement whose
tumours express c-erbB2 have a particularly poor prognosis, but c-erbB2 seems to be
of less value in delineating the prognosis of patients who are lymph node negative.
Tumours which express c-erbB2 are more likely to be resistant to both chemotherapy
and hormonal treatment. Thus, c-erbB2 analyses are requested to obtain prognostic
(outcome independent of treatment) and predictive (outcome dependent on
treatment) data [100].
p53
The product of the gene seems to be a transcription factor responsible for checking
the fidelity of cell replication. Nearly one third of breast cancers have mutations of
the tumour suppressor gene p53, which are associated with high histologic grade
and clinical aggressiveness [101-105].
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Immunohistochemical assays generally detect overexpression of the gene, which is
often related to conformational alterations and a prolonged half-life of the encoded
protein [106, 107]. Given the diverse functions of the p53 gene and the location and
type of genetic abnormalities (including gene loss and point mutation), the specific
genetic lesion may be shown to have prognostic importance.
p53 appears to be a useful prognostic marker, particularly in node-negative breast
cancer patients [108], and may also help identify patients likely to respond to
chemotherapy or radiotherapy. Patients with p53-immunopositive cancers may
develop autoantibodies against p53, which have been used by some to detect or
follow cancers [109],
Proteases
Cathepsin D is a lysosomal proteinase that is overexpressed in some breast cancers.
Overexpression of cathepsin D is associated with several poor prognostic features,
such as high histologic grade, large tumour size and node positivity, and has been
reported to be associated with an increased risk of recurrence and reduced disease-
free survival. However, while some studies have suggested that cathepsin D is an
independent prognostic factor in node-negative patients, others show no prognostic
significance among node-negative patients [110-112],
Interrelated factors
Many of the factors which correlate with outcome are interrelated and do not
therefore have independent prognostic significance. For example, grade III tumours
are likely to be oestrogen receptor negative, to be epidermal growth factor receptor
positive, have a high proliferative index and to be aneuploid. When a multivariate
analysis is performed and histological grade is entered first, little further prognostic
information is obtained by entering these other factors. Measurements of large
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numbers of prognostic factors is therefore of no value in the routine management of
patients with breast cancer.
Prognostic indices
Although individual factors are useful, combining independent prognostic variables
in the form of an index allows identification of groups of patients with different
prognoses. The Nottingham prognostic index is the most widely used index and
incorporates three prognostic factors: tumour size, node status and histological grade
[113]. With the Nottingham index the lymph node stage is 1 if no nodes are involved,
2 if one to three nodes are involved, and 3 if four or more nodes are involved. The
Yorkshire Breast CancerGroup categorised lymph node stage as 1 if no nodes were
involved or 3 for any axillary node involvement. The Yorkshire group also used
different codes for tumour grade: code 1 for grade I and code 2 for grades II and III.
Both indices identify three prognostic groups. The good prognostic group has a
survival similar to that of age matched controls without breast cancer, and such
women are unlikely to benefit from aggressive forms of adjuvant treatment. In
contrast the poor prognostic group, with a 13% survival after 15 years, may well
benefit from more intensive systemic treatment. (Nottingham prognostic index = (0.2
x size) + lymph node stage + grade.)
Prognostic factors are of value for three main reasons:
• To help select the appropriate treatment for individual patients
• To allow comparisons of treatments between groups of patients at similar risks of
recurrence or death
• To improve our understanding of breast cancer, which may permit the
development of new strategies or treatments
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1.6 Race/Ethnicity
Race has been shown to influence breast cancer prognosis, although this may be
related to socioeconomic status [114-118].
In one study, a 5-year relative survival from breast cancer forWhite and African
American females by stage for cases diagnosed during the intervals 1975-1979 and
1995-2001, found relative survival is consistently lower in African American than in
Whitewomen (although it has improved over time in both, except for distant stage
disease among African American women). For Whitewomen, 5-year relative
survival increased from 90.7% to 98.5% for localized disease, 68.8% to 82.9% for
regional stage disease, and from 18.0% to 27.7% for distant stage disease. Among
African Americans, relative survival increased from 84.8% to 92.2% for localized
disease, and 55.1% to 68.3% for regional stage disease, but there was minimal
improvement (15.1% to 16.3%) for distant stage disease [119].
Mortality rates vary by race and ethnicity. In the period 1998-2002, the average
annual female breast cancer death rate was highest in African Americans (34.7 cases
per 100,000 females), followed by Whites (25.9), Hispanics/Latinas (16.7), American
Indians/Alaska Natives (13.8), and Asian Americans/Pacific Islanders (12.7).
The higher death rate among African Americans, despite the lower incidence rate, is
due to both later stage at diagnosis and poorer stage-specific survival [119].
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1.7 Socioeconomic Status
SES is also a factor which influences prognosis and outcome. Breast cancer patients
from socially deprived areas have poor survival as compared with those who are
more affluent [120-122], This is reviewed in more detail in the introduction to
Chapter 3. Social and economic factors within racial/ethnic groups are being
examined as risk factors not only for breast carcinoma mortality and survival but
also as determinants of the rate of incidence. Social and economic factors have been
associated in the literature predominantly with cancer mortality and survival. When
socioeconomic status (SES) is considered, certain studies suggest that racial
disparities in breast carcinoma are smaller than when social and economic factors are
examined alone, but these disparities still persist [123].
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CHAPTER 2
CHANGES IN THE SITE OF CANCER
WITHIN THE BREAST WITH TIME
2.1 Introduction
Numerous clinical studies, dating back decades, have shown that the upper outer
quadrant (UOQ) of the breast is the most frequent site of carcinoma, but an adequate
explanation for this asymmetric occurrence of breast cancer within the breast has
never been established. This basic observation has become textbook fact [124] and
remains true for countries as different as India [125], the West Indies [126] and Italy
[127] and irrespective of race within any one country [128].
Furthermore, the UOQ is not only the most common site for cancer but also, in many
benign breast conditions, fibroadenomas, breast cysts [129] and phyllodes tumours
[130]. The UOQ is also the most frequent site of male breast cancer [131,132]
However, it is interesting to note that the reported incidence of breast cancer in the
UOQ of the breast appears to rise disproportionately with year of publication. In
1926, 30.9% of breast cancer was reported to be in the UOQ [133] but reports between
the years 1947-1967 suggested that the proportion of breast cancer in the UOQ was
43-48% [134, 135, 136, 137], A study in 1994, reported 60.7% of breast cancers in the
UOQ [127], Most of these studies are old.
In a recent study in the UK, female breast cancer incidence was studied in England,
Wales and Scotland. Over the period 1979 to 2000, the incidence of female breast
cancer has increased in England and Wales from 74.4 per 100,000 population
(European age-standardised rate (EASR)) (21,446 new cases recorded) in the year of
1979 to 113.8 per 100,000 population (EASR) (35,903 new cases recorded) in the year
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of 2000. Within the 212,677 cases made with site-specific information between 1979
and 2000, 52.5% of the cases were in the UOQ of the breast (111,583 cases recorded).
Other sites in the breast were found at lower frequencies: 3.9% in the nipple and
areola (8,222 cases recorded), 11.2% in the central portion (23,780 cases recorded),
14.6% in the upper inner quadrant (31,064 cases recorded), 6.4% in the lower inner
quadrant (13,570 cases recorded), 9.8% in the lower outer quadrant (20,836 cases
recorded) and 1.7% in the axillary tail (3,622 cases recorded). Inspection of the
annual incidence rates for each of these sites in the breast shows that as the incidence
of breast cancer has risen overall between 1979 and 2000, it is also increasing in all of
these sites. However, it does not appear to be increasing in all quadrants relative to
one another at the same rate. In Scotland, the incidence of female breast cancer has
risen from 84.9 per 100,000 population (EASR) (2,480 new cases recorded) in the year
of 1980, to 109.8 per 100,000 population (EASR) (3,485 new cases recorded) in 2001.
Within the 17,911 returns made with site-specific information between 1980 and
2001, the site of greatest incidence within the breast was again the UOQ in 52.6% of
the returns (9,418 cases recorded).
As for the data for England and Wales, no other quadrant showed any significant
increase over the total. Over a 21 year time span, incidence of breast cancer in the
UOQ has risen disproportionately from 38.3% in 1980 to 54.7% in 2001 [138],
However the factors involved remain contentious, but it has been suggested that
tissue mass is an important contributor to asymmetry in cancer incidence [139], This
has been attributed to more epithelial cells on the left side of the body due to
preferential vascular supply to the left side of the body during intrauterine cardiac
development [140].
Several investigations in patients with breast cancer have presented data which show
that the prevalent site of the primary tumour is the upper outer quadrant [124,134,
135,140-142].
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In a recent study done in Nottingham the quadrant from which 746 consecutive
breast core biopsies reported as normal, benign or malignant was recorded. The
distribution in the breast of normal, benign and malignant results were comparable.
In particular, the proportion of core biopsies from the upper outer quadrant reported
as normal (67%, 95% confidence interval 59-74%), benign (57%, 95% confidence
interval 51-63%) or malignant (62%, 95% confidence interval 57-67%) were similar.
This result supports the hypothesis that the high proportion of upper outer quadrant
carcinomas of the breasts is a reflection of the greater amount of breast tissue in this
quadrant [143]. However, other workers have also queried explanatory dogma
through their studies showing an even distribution of cancer between quadrants in
large and small breasts, despite the less marked quadrant distribution of tissue in the
smaller breasts [129].
An alternative explanation of this could simply be that the upper outer quadrant is
the local area in vicinity to the axilla where deodorants and antiperspirants are
applied. Since they are applied in large amounts, they may simply penetrate
through the skin of the local area and mimic the effect of oestrogen in the breast
tissue [138].
The importance of tumour location has an important role in the prognosis of breast
cancer as it has been proved that early breast cancers situated in central/ internal
quadrants have a worse prognosis compared with those in lateral quadrants, in terms
of distant metastases and survival. Data from 2,396 patients treated for early breast
cancer with a conservative approach were reviewed (1973 to 1989). In 1,619 patients
the tumour had a lateral site, while in 777 cases it was situated in the internal/central
quadrants. The characteristics of the two groups were well balanced, apart from
axillary nodal metastases, which were more frequent for lateral tumours (38.1% v
26.3%). The result of this analysis of distant metastases indicated that the regression
coefficient associated with tumour site was significant and the hazards ratio estimate
was 1.291, which indicates the risk of distant metastases was increased by
approximately 30% for internal/central tumours [144].
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In another study [145], medial locationwas associated with a 50% excess risk of
systemic relapse and breast cancer death compared with lateral location. Five-year
systemic disease-free survival rates were 66.3% and 74.2% for high-risk medial and
lateral lesions respectively (p < 0.005). Corresponding 5-year disease-specific survival
rates were 75.7% and 80.8% respectively (p < 0.03).
A similar study in Switzerland [146] showed 10 year disease-specific survival was
93% (95%CI: 91-94%). Patients with breast cancer of the lower-inner quadrant (n =
118; 7.8%) had an increased risk of dying of breast cancer compared to women with
breast cancer of the upper-outer quadrant (multi-adjusted Hazard Ratio: 2.3,95%CI:
1.1-4.5, p = 0.0206). The over-mortality associated with this quadrant was
particularly evident for tumours >10mm (multi-adjusted HR: 3.6, 95%CI: 1.6-7.9, p =
0.0016). There was no increased breast cancer mortality risk for tumours located in
other quadrants.
Another study from Italy [147], showed statistically significant differences for
patientswith medial tumours versus those with non-medial tumours in disease-free
survival (DFS; 10-year DFS, 46% v 48%; HR, 1.10; 95% CI, 1.02 to 1.18; p = 0.01) and
overall survival (10-year OS 59% v 61%; HR, 1.09; 1.01 to 1.19; p = 0.04). This
difference increased after adjustment for other prognostic factors (HR, 1.22; 95% CI,
1.13 to 1.32 for DFS; and HR, 1.24; 95% CI, 1.14 to 1.35 for OS; both p = 0.0001). The
risk of relapse for patients with medial presentation was largest for the node-
negative cohort and for patients with tumours >2 cm. In the subgroup of 2,931
patients with negative axillary lymph nodes, 10-yearDFS was 61% v 67%, and OS
was 73% v 80% for medial versus non-medial sites, respectively (HR 1.33; 95% CI,
1.15 to 1.54; p = 0.0001 for DFS; and HR 1.40; 95% CI, 1.17 to 1.67; p = 0.0003 for OS).
However, many studies are old and no data are available as to whether there has
been a change in the distribution of cancer within the breast over time in relation to
tumour size, menopausal status and age. The present study was designed to address
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this issue by studying two series of patients diagnosed in the Edinburgh Breast Unit
over four decades apart.
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2.2 Objective
The objectives were to determine:
(i) the site of cancer within the breast of two separate cohorts of women referred
within the same geographical area but 40 years apart
and
(ii) whether site was related to other clinico-pathological features of the disease.
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2.3 Materials and Methods
2.3.1 Patients
Two cohorts of women presenting with invasive breast cancer in the southeast of
Scotland were studied: (i) 1,158 out of almost 1,400 patients diagnosed with breast
cancer between 1957 and 1959, these are all patients who were referred to
oncologist for further treatment, the site of the tumour's location was documented on
the clinical notes in the patient's file, and (ii) 1,477 out of almost 1,600 patients
diagnosed with breast cancer between 1997 and 1999 and referred to the Edinburgh
Breast Unit.
The cases were selected on the basis of being able to retrieve the following details
from files: confirmation of histological breast cancer, patient age and menopausal
status, and tumour site, size and laterality. (Patients with bilateral tumours were
excluded from this study.) These data were recorded prospectively on a proforma
which was subsequently computerised.
2.3.2 Tumour location
Clinically the breast can be divided into 5 quadrants (upper outer, lower outer, upper
inner, lower inner and central). This was utilised in this study to categorise tumour
location, corresponding to upper outer quadrant (UOQ, Ql), lower outer quadrant
(LOQ, Q2), upper inner quadrant (UIQ, Q3), lower inner quadrant (LIQ, Q4) and
central (Q5). Big tumours which occupied more than one quadrant or small tumours
located on the interface between two quadrants, e.g. at 12, 3, 6 and 9 o'clock, were
classified in a single category (Q6).
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2.3.3 Definition of menopausal status
Patients who were menstruating or were within 3 years of their last menstrual period
were classified as premenopausal; those beyond 3 years of their last menopausal
period were regarded as being postmenopausal [148], In the cohort 1957-59, out of
1,158 patient 54 did not have their menopausal status recorded, this leaving 1,104
patients. In the cohort 1997-99, all 1,477 patients had their menopausal status
recorded.
2.3.4 T stage
T stage of the cohort 1957-59 was available only for tumour pathological size; there
were no records about the lymph nodes status and metastasis. As a result of this,
only pathological tumour size was available for comparison between the two
cohorts. Pathological tumour size in the cohort 1957-59 was recorded for 1,093 out of
1,158 (65 patients did not have their pathological size recorded). In the cohort 1997-
99 all 1,447 patients had their pathological sizes recorded.
'Staging' takes into account the size of the tumour, whether lymph nodes are affected
and whether the tumour has spread elsewhere. The most common system used to
describe the stages of cancers is the American Joint Committee on Cancer (AJCC)
TNM system [149], This staging system classifies cancers based on their T, N, and M
stages. The TNM system for staging is used all over the world [and separately
assesses the tumour (T), nodes (N) and metastases (M).
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Tumour (T)
TX: Primary tumor cannot be assessed
TO: No evidence of primary tumor (this sometimes happens)
Tis: Pure carcinoma in situ; intraductal carcinoma, lobular carcinoma in situ, or
Paget disease of the nipple with no associated tumour mass
Tl: The tumour is no more than 2 centimeters (cm) across
T1 is further divided into 3 groups
• Tla the tumour is more than 0.1 cm but not more than 0.5 cm
• Tib the tumour is more than 0.5 cm but not more than 1 cm
• Tic the tumour is more than 1 cm but not more than 2 cm
T2: The tumour is more than 2 cm, but no more than 5 cm across
T3: The tumour is bigger than 5 cm across
T4: is divided into 4 groups
• T4a The tumour is fixed to the chest wall
• T4b The tumour is fixed to the skin
• T4c The tumour is fixed to both the skin and the chest wall
• T4d Inflammatory carcinoma - this is a cancer in which the overlying skin is
red, swollen and painful to the touch
Nodes (N)
NO: normal and no enlarged lymph nodes in the axilla.
Nl: lymph nodes in the axilla, which are mobile.
N2: fixed lymph nodes, suspicious of spread of the disease
N3: enlarged lymph nodes in the neck, or in the controlateral axilla
Metastases (M)
MX: Presence of distant spread (metastasis) cannot be assessed.
MO: No sign of cancer spread
Ml: Cancer has spread to another part of the body, apart from the breast and lymph
nodes under the arm, usually to the liver, lungs, bones and brain
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2.3.5 Statistical Analysis




Both groups of patients were selected on the basis of being female, having a
diagnosis of invasive carcinoma, unilaterality of disease and clear documentation of
site within the breast of tumour. This provided 1,158 patients in 1957-59 (out of a
total of 1,208 referred to the radiation oncology in Edinburgh) and 1,477 in 1997-1999
(out of almost 1,600 patients referred to the Edinburgh Breast Unit).
The demographic characteristics of patients and their tumours are shown in Table 1.
The mean age at diagnosis for the 1957-59 cohort (57.7 years) was not significantly
different from that of the 1997-99 cohort (61.6 years). The menopausal status was
known on all patients in the 1997-99 cohort, but was missing on 54 cases in the earlier
group. At diagnosis, 27.1% of women in the first cohort were premenopausal
compared with 28.8% for the 1997-99 cohort. This change in proportion of





Mean age (years) 57.7 61.6
Menopausal status
Pre 299 (27.1%) 426 (28.8%)
Post 805 (72.9%) 1051 (71.2%)
T stage
1 181 (16.6%) 729 (49.4%)
2 625 (57.2%) 545 (36.9%)
3/4 287 (26.2%) 203 (13.7%)
Laterality
L 585 (50.5%) 753 (51%)
R 573 (49.5%) 724 (49%)













T stage (TNM classification was used as described in the materials and methods
section) was known on all patients in the 1997-99 cohort, but was missing in 65 cases
in the earlier cohort. In terms of T stage, there was a highly significant decrease, (chi-
square = 24.6, p<0.0001) between 1957-59 and 1997-1999; 181 (16.5%) were Tl, 625
(57.2%) T2, and 287 (26.2%) T3/4 patients in cohort 1957-59, as compared to 729
(49.3%) Tl, 545 (36.8%) T2, and 203 (13.7%) T3/4 in cohort 1997-99 (Figure 2).
Figure 2: T stage in two cohorts (p < 0.0001)
T stage 1957-59 1997-99
□ T1 □ T2 □ T3,4
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In terms of cancer laterality, the tumour was equally likely to be in the left or right
breast in both time periods (Figure 3).









□ Right ■ Left
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2.4.2 Tumour location in the breast
The sites of the tumours within the breast are summarized in Table 2 and shown in
Figure 4 for both groups of women. The distribution in the breast was significantly
different between 1957-59 and 1997-99 (x2 =100.288, p=0.0001).
Table 2: The site of breast cancer in different quadrants in two cohorts 1957-59
and 1997-99 (x2 =100.288, p = 0.0001)































Figure 4: Tumour sites in different quadrants in both cohorts, (x2 =100.288, p =
0.0001)
1 -i 1
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UOQ (upper outer quadrant)
The highest incidence of tumour was in the UOQ of the breast. Almost half the cases
were found in this location irrespective of the time of diagnosis (Table 2). However,
in the earlier patient cohort the incidence was 40.5% (469 of 1,158), whereas in the
more recent cohort it was 53.4% (788 of 1,477). This increase in proportion was
statistically significant (x2=42.45, p<0.0001).
LOQ (lower outer quadrant)
The incidence of tumours in the lower outer quadrant was low but increased
between 1957-59 and 1997-99, from 7.4% to 10% respectively. This difference was
statistically significant (x2=4.83, p=0.028).
UIQ (upper inner quadrant)
In contrast to the upper and lower outer quadrants, the upper inner quadrants
decreased in incidence of tumours from 19.1% in the 1957-59 cohort toll.8% in the
1997-99 cohort. This difference was highly statistically significant (x2=26.05,
pO.OOOl).
LIQ (lower inner quadrant)
The incidence of tumours in this site was similar in both groups (5.4% and 6.2%




Similar to upper inner quadrant, and unlike the upper and lower outer quadrants,
the central location decreased in the incidence of tumours from 12.5% in the 1957-59
cohort to 4.7% in the 1997-99 cohort. This difference was statistically highly
significant (x2=40.88, p<0.0001).
Q6
This category showed a reduction in incidence from 15.1% in the 1957-99 cohort to
14% in the 1997-99 cohort and the difference was highly statistically significant
(X2=23.38, p<0.0001).
2.4.3 Location of tumour in the breast according to T stage
Because there were statistically significant differences in the patients cohorts with
regard to T stage it was of interest to determine whether this factor influenced
changes in tumour location with time. These data are shown in Table 3 and
illustrated in Figures 5, 6 and 7.
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Table 3: The incidence of tumours in the breast zones in each T stage category


























































































Stats overall comparison x2=81.04, p<0.0001
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Figure 6: T2 in different quadrants in both cohorts
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Figure 7: T3/4 in different quadrants in both cohorts
The difference in tumour location between 1957-59 and 1997-99 was apparent in all T
stages, the difference being p<0.0001 in all cases. In terms of individual quadrants,
consistent statistical significances were seen for each T stage for UOQ. The increased
incidence in UOQ tumours over time is therefore unlikely to be a reflection of
decreased size.
Where statistically significant differences were apparent between time groups for
other zones, similar trends were also observed after subdivision into T stage; some
did not reach statistical significance, probably on account of the small number of
cases. The Q6 zone was unusual in that there was an increasing incidence in 1997-99
in T1 and T2 and a statistically significant decrease with T3/4.
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2.5 Discussion
The present study has shown that over the last four decades there has not been an
apparent change in menopausal status or in the laterality of patients with breast
cancer, which is conflicting with other results, but there were significant changes for
the size and distribution of breast cancer. It is important to consider the possible
reason for these changes.
Thus, even if the observations are specific to Edinburgh, the characteristics of
patients and tumours in this location have changed. It is possible that the difference
results from the selection process used to identify patients during the second time
period, but the distribution of cancers right versus left and menopausal status did
not change and there is no reason why patients with breast cancer or those with
UOQ lesion should have had changed incidence. This result is different compared to
other published studies mentioned in the introduction.
Whilst the initiation of the screening programme in Edinburgh in 1991 will have had
an impact on the population of women presenting with breast cancer, it is more
likely to have reduced the proportion of premenopausal women, screening being
offered to mainly postmenopausal women.
The most significant difference in the cancers between the cohorts was the increase in
tumour size. Similar changes over time have been previously reported. This is likely
to be in large part because of better education with increasing breast awareness and
the introduction of the screening programme in Edinburgh in 1991.
The present study has confirmed previously reported findings that the distribution
of breast cancer is not even throughout the breast but is higher in the upper outer
quadrant (UOQ).
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The study has also demonstrated that the preponderance of cancer in the upper outer
quadrant is increasing with time. In the most recent time period almost half of cases
were found in the UOQ irrespective of the laterality of the disease. The increases
trend was significant (p<0.0001). There was an increase in the likelihood of finding a
cancer in the lower outer quadrant (LOQ). The increased incidence in these
quadrants was particularly seen in premenopausal women but was apparent in each
T stage, unlike another study where there was increment in all quadrants.
The incidence of UOQ tumours was higher in premenopausal women in both cohorts
(p<0.0001). The reason for the higher incidence of breast cancer at this site is ascribed
to a greater proportion of breast tissue in the upper outer quadrant [124] and some
changes in lifestyle [138].
In this study the change in the quadrant was correlated to the size of the tumour and
the menopausal status, this will give a strong result with regards to bias with the site
of the tumour in the quadrant. No similar study was done previously comparing the
quadrants and the size.
The ability to reduce breast tumour growth through manipulation of oestrogen
action has played a central role in the endocrine therapy of breast cancer [150], but
little consideration has been given to the potential interaction of the presence of
oestrogenic chemicals in the human breast on the effectiveness of this therapy in
individual patients.
Interestingly, the UOQ is not only the most common site of the tumour in cancer but
also of the abnormalities in benign breast conditions, including fibroadenoma, breast
cysts [129], and phyllodes tumour [130].
Explanations for an increase of tumours in the upper outer quadrant include the
possibility that agents administered topically to the axilla might gain access to the
breast and be responsible for the initiation/promotion of tumours at that site.
Interestingly compounds in deodorants, such as parabens, have been reported to
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have the ability to penetrate the skin and have oestrogenic activity [151]. Whether
this might promote tumour growth remains a matter of conjecture.
Since antiperspirants act by blocking sweat ducts [152], and breast cysts result from
blocked breast ducts [124], it is possible that breast cysts could also arise from
repetitive trauma to the ducts in this area. Studies of the relation between cysts and
breast cancer have conflicting results. Some studies showed women with breast
cysts are at an increased risk of breast cancer, especially at younger ages [153, 154].
Phytoestrogens are used increasingly in cosmetics designed for application around
the human breast. There is an increasing trend towards addition of Aloe Vera into
personal care products, and the constituent anthraquinones are known to possess
oestrogenic properties [155].
Cosmetic chemicals such as aluminium salts [156], cyclosiloxanes and triclosan are
already known to have DNA damaging properties as well as oestrogenic activity
[157, 158]. The alkyl esters of p-hydroxybenzoic acid (parabens) are added in
concentrations of up to 0.8% as preservatives to thousands of cosmetic products,
which mimic oestrogen in breast tissue [158] and have been detected in human breast
tumour tissue at an average concentration of 20 ng/g tissue [159],
The constant use of bras (particularly of under-wired which constricts breast tissue
and lymphatics mostly in the outer quadrants by the very nature of its design) for
long periods might influence lymphatic flow from the breast, this might be a cofactor
with other factors in traumatizing tissues in the UOQ of the breast where the wire
has the most pressure point.
Axillary hair is now frequently removed by different means and is currently
performed more frequently than was done four decades ago. This potentially causes
repetitive trauma to the axilla and neighbouring outer quadrants.
The accepted explanation for the disproportionate incidence of breast cancer in the
UOQ of the breast is that this region of the breast contains a greater proportion of the
epithelial tissue [143] which is the target site for breast cancer. However, evidence
for this explanation is lacking and seems to be anecdotal in origin.
If this trend to increasing incidence of breast cancer in the UOQ is a function of time
and is not a reflection of different study populations, then this would question the
explanation for high incidence of breast cancer in the UOQ as being due solely to the
presence of more epithelial tissue in that region. However, further studies need to be
done to assess the cause of this disproportion especially for epidemiology prognosis.
Other epidemiological factors which may have changed between the two time
cohorts and which may influence the risk of breast cancer include the length of pill
usage, use of HRT, late first pregnancy, number of offspring/family size and long gap
between pregnancies, alcohol and cigarette smoking. There is no obvious reason
why these particular factors should influence tumour location, but it might influence
breast cancer frequency and tumour size. Further studies need to be carried out to
determine what might be the cause of this change in the distribution of breast cancer.
It should also be noted that changes over time in breast cancer do not only affect
location. For example, there is some circumstantial evidence that temporal changes
may be occurring in laterality. Many studies indicate that the left breast is more
prone to development of cancer than the right breast in both female [124,134,135,
141, 142, 160] and male [141, 140] breast cancer. However, in a more recent American
publication describing patients studied between 1973 and 1998, the numbers of right-
sided and left-sided were roughly equal [161], Interestingly the most common
location for tumours was the upper outer quadrant of the breast. The stage and
histology of breast cancer has also changed. As was also shown in the present study,
more early breast cancer is being seen now as compared with in the past [162],
Similarly, while ductal carcinoma incidence rates remained essentially constant from
1987-1999, lobular carcinoma rates increased steadily [163,164]. This may be because
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HRT use has increased steadily from the 1970s to the 1990s [165-169]. Beyond their
aetiologic importance these results also have clinical significance because ILC and
IDC have different clinical features. For example, ILC is more likely to be hormone
receptor-positive [170] and to have a better prognosis than IDC [171].
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CHAPTER 3
SOCIOECONOMIC STATUS AND PROGNOSIS/
OUTCOME OF BREAST CANCER PATIENTS
3.1 Introduction
There is evidence that socioeconomic status (SES) is associated with the natural
history of breast cancer both in terms of risk to the disease and outcome of women
with breast cancer. This is reviewed in the following sections.
3.1.1 Assessment of Socioeconomic Status
There is a long-standing awareness that poverty is associated with general risk of ill-
health and outcome from disease. There has, however, been controversy as to how
best to assess and quantify poverty/socioeconomic status [172,173].
The debate has centred mainly on the validity of social classes as a general measure of
relative affluence or poverty in a society where other correlates of poverty (such as
unemployment, single parenthood and old age) are increasingly prevalent [174, 175].
Several different ways of combining variables have been developed as a means of
categorising the populations of small geographically defined areas such as census
enumeration districts, local government wards or postcode sectors [173, 176, 177].
All combine variables to generate a summary score, which hopefully reflects the
socioeconomic status of a locality relative to the distribution of scores obtained for all
localities and reflect a principal component of the full census dataset which describes
a socioeconomic dimension in these data [178,179].
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Morris and Carstairs [178] restructured the distribution of deprivation scores for
postcode sectors to create a categorical variable ranging from deprivation category
(DEPCAT) 1 (the most affluent) to deprivation category 7 (the most deprived). The
variables comprising the score vary according to different censuses but basically
utilise measures associated with material resources, access to amenities and physical
environment as applied to postcode sectors. For example in the 1981 census
variables included overcrowding, male unemployment, low social class based on
head of household and no car.
The frequency distribution of DEPCAT categories in Scotland for the 1981 and 1991
censuses are summarized in Table 4.
Table 4
1981 1991
DEPCAT Population % Postcodes % Population % Postcodes %
1 305,868 6.1 105 10.4 305,725 6.1 94 9.4
2 691,280 13.7 180 17.8 688,018 13.8 171 17.1
3 1,095,583 21.8 253 25 1,090,483 21.8 226 22.6
4 1,282,976 25.5 219 21.7 1,270,597 25.4 231 23.1
5 743,689 14.8 117 11.6 741,664 14.8 125 12.5
6 571,901 11.4 91 9 567,492 11.4 97 9.7
7 340,998 6.8 45 4.5 334,285 6.7 57 5.7
Total 5,032,295 100 1,010 100 4,988,264 100 1,001 100
(Table modified from Morris R, Carstairs V. / Public Health Med 1991;13:318-26)
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3.1.2 Socioeconomic Status and Risk
There is evidence that degree of affluence influences chances of developing breast
cancer. This is derived from two major sources - (i) the international distribution of
the disease and (ii) the socioeconomic status within discrete populations. Both sets of
data suggest that increased affluence is associated with increased risk and that
socially deprived populations may be less vulnerable to the disease [180-186].
In terms of the influence of SES within individual international populations, data has
been published from many different countries, including USA (where African
American, Hispanic/Latina, Asian American/Pacific Islander and American
Indian/Alaska Native women have lower incidence rates than Whites), Japan,
Netherlands, Demark, Sweden and the UK (including Scotland).
Breast cancer incidence rates in Scottish women are rising in parallel across all
socioeconomic categories and the incidence gap between deprived and affluent still
remains [180],
For example, data on breast cancer incidence rates by deprivation quintile in
Scotland 1991-2000 were analysed using linear regression. Incidence data for breast
cancer incidence per 100,000 women (age-standardised to the European Standard
Population) from 1991 to 2000 in each deprivation quintile of the Scottish population
was obtained from the Information and Statistics Division of the Scottish Executive
(ISD). Deprivation quintiles divide the Carstairs and Morris index - an index
calculated for individual postcodes based on factors such as occupation of head of
household - into five equal categories. Between 1991 and 2000, breast cancer
incidence rates in Scotland continued to be lower with increasing deprivation.
Linear regression reveals a significant rise in incidence over this period in all
quintiles (except for quintile 2). In the most affluent the rise in incidence was of the
magnitude of 1.9 cases per 100,000 per year, and in the most deprived 1.0 case per
100,000 per year. Interaction analysis revealed regression slopes to be parallel (p =
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0.778), confirming that incidence rates are rising to the same degree in all deprivation
categories [180],
The exact causes behind these observations are not fully defined and, indeed, it is
likely that the differential effects may be multifactorial. However, amongst the
reasons underlying the phenomenon include lifestyle factors such as diet, stress,
reproductive and child-bearing parity, the use of oral contraceptives, HRT, radiation
and environmental factors, but it cannot be excluded that the increased incidence in
more affluent populations is due to more efficient diagnosis of the disease.
The study mentioned above [180] also examined other aetiological factors, such as
first births at late maternal age, BMI trends (based on the Scottish Health Surveys)
and breast screening uptake trends. Since the late 1980s, numbers of first birth in
Scottish women aged 35-39 have risen dramatically (especially in the affluent), but
numbers were stable before this. The prevalence of obesity and mean BMI has
increased over time in all socioeconomic classes, but BMI continues to be higher in
the deprived. Uptake of screening invitations has increased in all socioeconomic
groups. It was therefore concluded that trends in late age at first pregnancy,
prevalence of obesity and screening uptake do not fully explain the observed trends
[180],
According to data from the NHIS, utilization of screening mammography has
increased greatly amongWhite and African American women of all ages since 1987.
Among White women, the percentage of women aged 40 and older who reported
having had a mammogramwithin the past 2 years increased from 30% in 1987 to 71%
in 2003. Similarly, during 1987 to 2003, the prevalence of mammography usage
among African American women increased from 24% to 70%, respectively.
Although current overall usage of mammography is similar among White and
African American women, usage remains lower in women of other racial and ethnic
groups [117]. Women with less than a high school education, without health
insurance coverage or who are recent immigrants to the United States are even less
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likely to have had a recent mammogram. The results indicate social inequalities
regarding awareness of the disease and/or access to early detection and this, in turn,
might translate into a higher apparent risk in more affluent women.
3.1.3 SES and Prognosis/Outcome
The clinical behaviour of breast cancer is variable. Many patients survive for
extended periods of time with minimum treatment, whereas others die relatively
quickly despite the implementation of a combination of surgical, radiation and
systemic therapy [187],
Socioeconomic status is a factor which has been suggested to influence prognosis.
Women with breast cancer from lower socioeconomic groups have relatively lower
survival than affluent women and this difference in outcomes seems independent of
the measure of socioeconomic status used [188],
The quantitative effects of SES on outcome of breast cancer are best illustrated with
examples. For example, in Finland the effect of social class on survival of female
breast cancer patients was studied by linking the patient files of the Finnish Cancer
Registry (FCR) with the information on patient's social status, obtained from the 1970
Population Census of Finland. The material consisted of 10,181 patients 25-69 years
of age at diagnosis, whose cancer was diagnosed between 1971 and 1980. The
classification of social class was based on occupation. Those in the lowest social class
had about 1.3 times higher relative excess risk of dying than those in the highest
social class.
Another study in the UK was carried out on 10,865 cases of breast cancer from the
East Anglian Cancer Registry diagnosed between 1982 and 1993. It was estimated
that the extent to which the differences in survival by socioeconomic status,
measured by both occupational and area-based methods, could be explained by
differences between socioeconomic groups in stage and morphological type of
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tumour. In univariate survival analyses, lower social class (manual occupation) was
associated with a relative hazard of 1.32 (95% CI 1.12-1.55) for death from breast
cancer as underlying cause. Women resident in the most deprived area had a
relative hazard of 1.21 (0.95-1.54) for death from breast cancer as underlying cause
[189],
The clinical importance of this observation depends on the magnitude of the
difference in survival. A recent review of cancer registration data from England and
Wales indicated a difference of 5-10% both for absolute and relative survival between
the affluent and deprived groups depending on the period of diagnosis [190].
A study performed in west Scotland on 1,361 women aged under 75 who had breast
cancer diagnosed between 1980 and 1987 showed that there was no significant
relation between socioeconomic deprivation and four pathological prognostic factors:
93 (32%) women in the most affluent group presented with tumours less than 20 mm
in size compared with 91 (31%) women in the most deprived group; 152 (48%) of the
most affluent group presented with negative nodes compared with 129 (46%) of the
most deprived group; 23 (22%) of the most affluent group presented with grade I
tumours compared with 12 (17%) of the most deprived group, and 142 (51%) of the
most affluent group had a low oestrogen receptor concentration at presentation
compared with 148 (52%) of the most deprived group. None of these differences was
statistically significant and it was concluded that differences in survival from breast
cancer by socioeconomic deprivation category could not be accounted for by
differences in tumour stage [122],
In a study carried out in Scotland, differences in survival from breast cancer were
compared between women resident in affluent and deprived areas. Two datasets
relating to breast cancer patients in Scotland were analysed: (1) population-based
cancer registry data; (2) a subset of cancer registration records supplemented by
abstraction of prognostic variables (stage, node status, tumour size, oestrogen
receptor (ER) status, type of surgery, use of radiotherapy and use of adjuvant
systemic therapy) from medical records. The study was carried out on patients from
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cancer registration data on 21,751 women aged under 85 years diagnosed with
primary breast cancer between 1978 and 1987; and national clinical audit data on
2,035 women aged under 85 years diagnosed with primary breast cancer during
1987. Survival differences of 10% between affluent and deprived women were
observed in both datasets, across all age groups.
In the audit dataset, the distribution of ER status varied by deprivation group (65%
ER positive in affluent group v 48% ER positive in deprived group; under 65 age
group). Women aged under 65 with non-metastatic disease were more likely to have
breast conservation than a mastectomy if they were affluent (45%) than deprived
(32%); the affluent were more likely to receive endocrine therapy (65%) than the
deprived (50%). However, these factors accounted for about 20% of the observed
difference in survival between women resident in affluent and deprived areas. They
concluded that deprived women with breast cancer have poorer outcomes than
affluent women, explained by deprived women having more ER negative tumours
than affluent women [191].
In the Netherlands, a country characterized by good general access to health care
services, the survival rates of patients with cancer by socioeconomic status (SES) has
never been investigated. The association between socioeconomic status and survival
from cancer of the lung (n = 4591), breast (n = 3928), colorectum (n = 3558), prostate (n
= 1484), and stomach (n = 1455) was studied. A more favourable relative survival for
patients living in high SES areas was found for those with cancer of the lung, breast,
colorectum and prostate, whereas for those with stomach cancer, lower survival was
found for patients living in high SES areas [192]
In a study from South Thames, Pollock et al [193] also showed a clear trend was
observed in standardized mortality rates across deprivation tenths for three tumour
sites (breast, lung and colorectal); mortality increased with deprivation. Significantly
lower 5-year relative survival rates were found for breast and colorectal cancer
patients in the most deprived groups. Breast cancer patients resident in the most
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affluent tenth of enumeration districts had a 70% relative survival ratio compared
with 57% in the most deprived tenth.
The underlying causes behind more socially deprived patients having poorer
outcome may be multifactorial and may differ according to individual populations.
However, amongst the reasons are (i) disease associated factors such as more
advanced stage at presentation, higher histological grade, less ER positivity, (ii)
lifestyle related risk factors for cancer such as smoking, nutritional habits, drinking
habits and reproductive factors, which are prevalent in lower socioeconomic groups
[194] and (iii) differences in management of disease such as inferior treatment and
follow-up. The evidence for this is summarized below.
(i) disease associated factors
Extent of disease at the time of presentation has a major impact on prognosis [191],
but equally women with the same treatment and clinical stage may survive for
widely differing lengths of time.
Some studies have observed a positive relationship between social deprivation and
more advanced stage of disease (and corresponding poorer outcome). For example,
several Scottish studies attributed socioeconomic effects to differences in stage at
presentation [186, 195] in that patients with cancer from deprived communities in
Scotland appear to present with more advanced disease [121, 196].
A study was performed in west Scotland on 1,361 women aged under 75 who had
breast cancer diagnosed between 1980 and 1987. It showed no significant relation
between socioeconomic deprivation and four pathological prognostic factors: 93
(32%) women in the most affluent group presented with tumours less than 20 mm in
size compared with 91 (31%) women in the most deprived group; 152 (48%) of the
most affluent group presented with negative nodes compared with 129 (46%) of the
most deprived group; 23 (22%) of the most affluent group presented with grade I
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tumours compared with 12 (17%) of the most deprived group, and 142 (51%) of the
most affluent group had a low oestrogen receptor concentration at presentation
compared with 148 (52%) of the most deprived group.
A Swedish study detected significant social differences (p < 0.01) in distribution of
clinical stage as well as in total and stage-specific survival. High income, more
skilled work and a high level of education were all associated with clinically less
advanced tumours and hence better survival. However, social gradients were most
obvious in mortality associated with non-breast cancer events [197].
In a study from South Thames [198], irrespective of age, women in the most deprived
category had a 35% greater hazard of death than women from the most affluent areas
after adjustment for stage at diagnosis, morphological type and type of treatment.
However, in younger women (30-64 years) the survival gradient by deprivation
category cannot be explained by these prognostic factors. In older women (65-99
years), part of the unadjusted gradient in survival can be explained by differences in
the stage of disease: older women in the most deprived category were more often
diagnosed with advanced disease. Other factors, so far unidentified, are responsible
for the gradient in breast cancer survival by deprivation category. The potential
effect on breast cancer mortality of eliminating the gradient in survival by
deprivation category is substantial (7.4%). In women aged 30-64 years, 10% of all
deaths within 5 years might be avoidable, while in older women this figure is 5.8%.
In a study from the Netherlands, the socioeconomic variation in survival of patients
with breast cancer could be ascribed mainly to differences in the percentage of
patients diagnosed with a metastasis [199].
Factors that may contribute to later stage at diagnosis among minority women are
less frequent mammography [200], delays from time of abnormal mammographic
findings to diagnostic confirmation and treatment [201], more limited access to
healthcare [202], and more aggressive tumour characteristics [203].
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Oestrogen receptor positive tumours generally have a better prognosis than
oestrogen receptor negative tumours [205-207], It is therefore interesting that socially
deprived women have been reported to have a higher incidence of ER-ve tumours
than affluent women [190, 208]. However, in contrast, in west Scotland 51% of the
most affluent group of patients had tumours with a low oestrogen receptor
concentration at presentation compared with 52% of the most deprived group.
However, the difference was not statistically significant and it was concluded that
differences in survival from breast cancer by socioeconomic deprivation category
could not be accounted for by differences in tumour ER [122],
Another study in Scotland suggested that level of social deprivation is associated
with oestrogen receptor status; the distribution of ER status varied by deprivation
group (65% ER positive in affluent group v 48% ER positive in deprived group;
under 65 age group) [191],
(ii) host factors
Whilst there is no direct evidence for general differences in natural hormone levels
between women of different socioeconomic status, other influences which may vary
with social status such as body weight, exercise, self-examination and diet can affect
production and circulating level of oestrogens [209-212], Nevertheless body mass
index may influence survival of breast cancer patients [213],
Although race does not appear to be immediately associated with breast cancer
outcome after adjusting for SES and other confounding factors such as demographic
and disease characteristics [214], another study stated that "poor persons, regardless
of their race, are likely to have undesirable cancer outcomes" [202],
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The possibility exists therefore that other factors inherently present in the lifestyle/
environment of women of low socioeconomic status are directly affecting the history
of the breast cancer [215-217], such as smoking, nutritional habits, drinking habits
and reproductive factors, which are prevalent in lower socioeconomic groups [218].
(iii) differences in management of disease
It is possible that the difference between socially deprived and affluent patients
reside not in the disease itself but in the efficiency of diagnosis and the nature of
treatment and follow-up which the groups receive.
In terms of diagnosis, it has been shown that socioeconomic disparities in breast
cancer survival prevail even in this relatively homogenous society, offering outreach
mammography and standardised treatment regimens in a tax-funded health care
system [208].
During the interval 1995 to 2001, the proportion of cases diagnosed at regional and
distant stages combined was 43% among AfricanAmerican women, 43% in
American Indian/Alaska Natives, 42% inHispanic/Latinas, 34% in Asian
Americans/Pacific Islanders and 33% among White women. Factors that may
contribute to later stage at diagnosis amongminority women are less frequent
mammography [200] and delays from time of abnormal mammographic findings to
diagnostic confirmation and treatment [201].
It has also been postulated that socioeconomic differences may be related to
treatment, those who are more socially aware being more likely to be referred to
specialist cancer centres [219].
Population-based statistics in the United States indicate that overall age-adjusted
breast cancer mortality rates are higher among black women than white women, and
the disparity is increasing. The aetiology of the widening racial disparity is poorly
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understood. However, these trends might be attributable to disparities in health care
quality or access, different responses to newer medical interventions, or alterations in
risk factors (such as nutrition, physical activity, obesity, or childbearing practices)
[202, 219-221],
One study in the US, looking at disparities between women of different
socioeconomic status, showed than women without private health insurance were
less likely than privately insured women to be screened for breast cancer and their
treatment may differ after cancer is diagnosed. In this study they addressed two
related questions: Do uninsured patients and those covered by Medicaid have more
advanced breast cancer than privately insured patients when the disease is initially
diagnosed? And, for each stage of disease, do uninsured patients and patients
covered by Medicaid die sooner after breast cancer is diagnosed than privately
insured patients? The study was performed on 4,675 women, aged 35-64 years, in
whom invasive breast cancer was diagnosed from 1985-1987. The stage of disease
and stage-specific survival among women with private insurance, no insurance, and
Medicaid coverage through June 1992 was compared. The adjusted risk of death for
these groups was estimated, using proportional-hazards regression analysis to
control for age, race, marital status, household income, coexisting diagnoses and
disease stage. The result was uninsured patients and those covered by Medicaid
presentedwith more advanced disease than did privately insured patients (p<0.001
and p=0.01, respectively). Survival was worse for uninsured patients and those with
Medicaid coverage than for privately insured patients with local disease (p<0.001 for
both comparisons) and regional disease (p<0.001 for both comparisons), but not
distant metastases. The adjusted risk of death was 49% higher (95% confidence
interval, 20-84%) for uninsured patients and 40% higher (95% confidence interval, 4 -
89%) for Medicaid patients than for privately insured patients during the 54 to 89
months after diagnosis. It was concluded that the more frequent adverse outcomes
of breast cancer among women without private health insurance suggest that such
women would benefit from improved access to screening and optimal therapy [219].
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In the above study the authors found that, compared with white women, African-
American women were 53% more likely than white women to be diagnosed with
later-stage disease, 26% less likely to receive radiation after breast-conserving
surgery, more than twice as likely to receive no surgery, and 39% more likely to die.
But when the authors adjusted their data to account for race and socioeconomic
factors, differences in these outcomes, except for choice of surgery, nearly vanished.
Compared with white women, African-American women were 62% more likely to
have no surgery. If the African-American women had surgery, they were 63% more
likely to receive breast-conserving surgery.
Women insured by Medicaid were 41% more likely to be diagnosed with late-stage
breast cancer, 44% less likely to receive radiation after breast-conserving surgery, and
three times more likely to die than women not insured by Medicaid. The authors
concluded that, "poor persons, regardless of their race, are likely to have undesirable
cancer outcomes. This finding should challenge the research and policy
communities to provide remedies for reducing these disparities." [202, 222],
Socioeconomic variation in survival from a number of common cancer sites exists in
the Netherlands, despite the fairly equal access to health care services for different
socioeconomic groups [192],
A different study investigated the relationship between socioeconomic status (SES)
and the use of intentionally reduced doses of chemotherapy in the adjuvant
treatment of breast cancer. Patients with breast cancer treated with a standard
chemotherapy regimen (n = 764) were enrolled in a prospective registry after signing
informed consent. Detailed information was collected on patient, disease and
treatment, including chemotherapy doses. Zip code level data on median household
income, proportion of people living below the poverty level, and educational
attainmentwere obtained from the US Census. Doses for the first cycle of
chemotherapy lower than 85% of standard were considered to be reduced.
Univariate analyses and multivariate logistic regression were performed to identify
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factors associated with the use of reduced first cycle doses. The result showed
individual education attainment, zip code SES measures, body mass index and
geographic region were all significantly associated with receipt of intentionally
reduced doses of chemotherapy. In multivariate analysis, controlling for geography,
factors independently associated with reduced doses were obesity (odds ratio [OR],
2.47; 95% CI, 1.36 to 4.51), severe obesity (OR, 4.04; 95% CI, 1.46 to 11.19), and
education less than high school (OR, 3.07; 95% CI, 1.57 to 5.99) and it was concluded
that social disparities in breast cancer outcome is in part the result of lower quality
chemotherapy doses in the adjuvant treatment of breast cancer [223],
The relation of economic status to survival was studied for 39 kinds of cancer
representing all types for which 60 or more indigent patients were seen in the
University of Iowa Hospital for primary care during the years 1940-1969. For every
type the indigent patients had poorer survival than non-indigent patients. Quality of
care would be eliminated as a major variable since a second group of "ward" patients
of higher economic status was available for comparison and the differences were
substantially greater between the two groups of teaching patients than between the
"clinic pay" and "private" patients. Age differences and differences in stage of
disease accounted for less than half of the survival deficits in the indigents. The two
important problems were high mortality from causes other than cancer and excess
cancer mortality not accounted for by stage differences, particularly among patients
who should have had 5-year survival rates between 40-70%. In these patients cancer
recurred more often and earlier among the indigent. Postulate host differences
associated with poverty could also account for much of the observed Black-White
differences as well as some international differences in cancer survival rates [194,
224,225],
Sainsbury et al [226] used cancer-registry data from 12,861 patients with breast
cancer treated in Yorkshire, UK, between 1979 and 1988, and found that patients of
surgeons with higher rates of usage of chemotherapy and hormone therapy (regional
mean usage 9.3%, range 0-46%) had prolonged survival. There was considerable
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variation in survival of breast cancer patients between surgeons, but their rate of use
of chemotherapy and hormone therapy explained about 26% of this survival
variation. Had the practice of the surgeons with the better outcomes been used by all
treating clinicians, 5-year survival would have increased by about 4-5%.
Examination of differences in survival as a function of consultant caseload
demonstrated poorer results amongst those surgeons treating less than 30 new cases
of breast cancer per year (risk ratio [95% CI] for treating >30 compared with <10 =
0.85 [0.77-0.93]).
Miscellaneous
A study held in the UK examined national trends and socioeconomic inequalities in
cancer survival during the 1990s using population-based data on 2.2 million patients
who were diagnosed with one of the 20 most common cancers between 1986 and
1999 and followed up to 2001. Survival for most cancers in both sexes continued to
improve during the 1990s. The deprivation gap in survival between rich and poor
was wider for patients diagnosed in the late 1990s than in the late 1980s. Increases in
cancer survival in England and Wales during the 1990s are shown to be significantly
associated with a widening deprivation gap in survival [227],
Considering that five year observed survival for women with breast cancer in
Scotland improved by just six percentage points (from 50% to 56%) in the 16 years
from 1970 to 1985 [120], the potential benefit of understanding and remedying the
difference between socioeconomic groups is substantial.
Objectives
The objectives of this study were to (i) quantify and investigate differences in
survival from breast cancer between women resident in affluent and deprived areas
of the southeast of Scotland, and (ii) define the contribution of underlying factors of
this variation.
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3.2 Materials and Methods
3.2.1 General Approach
The general approach was to study a large cohort of patients who were referred to
the Edinburgh Breast Unit between 1985 and 1993 (and therefore have already at
least 5 years follow-up). These patients were (i) staged and treated by standard Unit
policy, (ii) stratified into different socioeconomic groups according to Carstairs Index
[178] and (iii) were available for extended follow-up. Correlations therefore could be
made between socioeconomic status and known prognostic factors, time to
recurrence and survival.
Patient database
Cases for this study were derived from a single unit (Edinburgh Breast Unit) which is
the major referral centre for the southeast of Scotland and sees over 90% of patients
from this area. Patients with histologically-proven breast cancer diagnosed between
1985 and 1993 were identified. The present study was part of a wider investigation
in which tumour biology was being investigated. An additional recruitment
criterion was the need for fresh cancer tissue for analysis (but these analyses were not
part of the present study). The other reason for inclusion of these patients, apart
from being diagnosed with breast cancer and the availability of the tumour tissue
(stored in the Edinburgh Breast Unit bank), was access to the files with complete
needed information, ie address at diagnoses, full pathological information (lymph
nodes status, ER status, menopausal status, and pathological tumour size), and
regular follow up for at least 5 years. Patients' files which did not have sufficient
information or patients with small tumours where tissue was not enough to store in
the bank were excluded. All patients with detailed information available in the files
and the availability of fresh tissues in the store were included in the study - this
made the total number of patients small.
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A total number of 502 patients were studied and the following details were
documented: the patient's postcode at time of diagnosis, age, menstrual status,
tumour size, lymph node status, presence/absence of distant metastasis and ER
status of the primary tumour. All patients were routinely followed up and
information on date of recurrence, disease free survival, overall survival and cause
and date of death recorded (the minimum follow up was 262 weeks. Survival
analysis was based on deaths from all causes due to lack of information on cause of
death.
As a consequence, elderly patients with more advanced disease and small tumours
may be under-represented in these studies. However, these categories were not
totally absent and, when analysed as markers of prognosis or correlated with other
established parameters, have yielded results concordant with published literature
embracing higher numbers of cases and representative populations of patients.
Lymph node status
Lymph node status was determined pathologically by examination of nodes derived
from either full axillary dissection or axillary sampling (if possible, by identification
of 4-6 lymph nodes). The cases were subdivided according to whether no involved
lymph nodes were found (negative) or whether one or more were found to be
involved with cancer (positive).
Oestrogen receptor status
Oestrogen receptors were measured either by ligand binding or
immumohistochemistry as described by Jennet et al [228]. Tumours were scored as
positive if the ER measurement was >20 fmol/mg cytosolic protein or >10% staining
and negative if below these cut-offs.
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Menopausal status
Patients who were menstruating or were within 3 years of their last menstrual period
were classified as premenopausal; those beyond 3 years of their last menopausal
period were regarded as being postmenopausal.
Clinical T stage
This was adapted from that defined by TNM criteria [149]. The staging of breast
cancer involves clinical, pathological and radiological data. A commonly used
classification system is the TNM (Tumour, Nodes, Metastases) system which stage a
tumour according to the size and extent of local spread of the tumour, the presence
of lymph node metastases, and the presence of distance metastases, usually to the
liver, bone, lung and brain.
In the UK the majority of breast cancer cases are early breast cancers, at diagnosis,
usually at TNM staging T1 and T2.
Deprivation score (Carstairs Index)
The method of Carstairs and Morris was used to derive a deprivation score. This
measure is based on the postcode of residence at diagnosis. As discussed in the
introduction, the Carstairs formula utilized census data. Both deprivation criteria
and postcode score vary between different censuses. The time period of patient
recruitment (1985-1993) encompasses two censuses (1981 and 1991). Patients who
were diagnosed before 15.6.85 were therefore classified under Census 1981, and
those after this date were classified under 1991.
The deprivation scores for postcode sectors create a categorical variable ranging from
deprivation category 1 (the most affluent) to deprivation category 7 (the most
deprived). Because of relatively small numbers in some of the categories, in the
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present study groups have been combined to yield zones in which zone A comprises
categories 1 and 2 (the most affluent/least deprived), zone B comprises DEPCAT
category 3 alone, zone C comprising category 4 alone, and zone D comprising
DEPCAT categories 5, 6 and 7 (the least affluent/most deprived).
Data Analysis
Clinical data were related to SES status by chi square analysis. Clinical factors and
SES status were examined individually to investigate whether any related to
outcome measures (recurrence and survival at 5 and 10 years by chi-squared testing
and all outcome data by Kaplan-Meier). Survival analysis was based on deaths from
all causes due to lack of information on cause of death. For the survival analysis,
patients were censored at the date they were last known to be alive. For the analysis
of relapse, patients were censored at the date when they were last known to be alive
and disease free or at the date when they died free of disease.
Cox's proportional hazards modeling was applied to the audit data to examine the
effect of introducing other variables into the model on the relative hazard ratios for
the intermediate and most deprived groups relative to the affluent group. The
possible prognostic variables for survival which were considered were: Year treated,




3.3.1 Subdivision of cases by socioeconomic status
In all, 502 patients diagnosed with invasive breast cancer between 1985 and 1993
were included in the study. These were subdivided according to Carstairs Index into
different socioeconomic groupings on the basis of their postcode as described in the
Methods section. The number of patients in each of the seven DEPCAT is shown in
Table 5 and the distribution within the groups shown in Figure 8. This shows a bell
shaped curve with the majority of cases (52%) in DEPCAT 3 and 4.
Table 5: distribution of cases by DEPCAT score
DEPCAT
score
1 2 3 4 5 6 7 TOTAL
Number
patients
52 82 126 136 76 13 17 502
Percent 10.4 16.3 25.1 27.1 15.1 2.6 3.4 100
Figure 8: distribution of cases by SES DEPCAT










1 2 3 4 5 6 7
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Because of the relatively small number of cases in DEPCAT 1, 2, 5, 6, and 7, for
certain analyses DEPCAT 1 and 2 have been grouped together (zonal group A - 26%
and the most affluent) as have 5, 6 and 7 DEPCAT (zonal group D - 21% most
deprived) to create categories with similar numbers to those in DEPCAT 3 (25.1%
zonal group B) and DEPCAT 4 (27.1% zonal group C) as is shown in Table 6 and
Figure 9. Two sets of statistical tests were performed according to the seven
DEPCAT or the four zonal groups. Additionally, trends across 7 DEPCAT levels
have been analyzed but in order to identify a group of socially deprived cases
DEPCAT 6 and 7 have been combined and compared against 1-3, 4-5 categories with
power calculations based on n=260, 212 and 30 of 502 patients.
Table 6: distribution of cases by zones
Zones A B C D TOTAL
Number
patients
134 126 136 106 502
Percent 26.7 25.1 27.1 21.1 100
Figure 9: distribution of SES into zones
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3.3.2 Survival
Survival was assessed by multiple criteria: A - according to whether patients were
alive or dead at 5 years; B - whether patients were alive or dead at 10 years and C -
by Kaplan-Meier survival curves taking the time of death as an incident point and as
a continuous variable.
A - alive or dead at 5 years
The number of patients dead at 5 years was 127 (25.3%). The survival figures at 5
years subdivided according to socioeconomic status are summarised in Table 7 and
shown diagrammatically in Figure 10. The percentage of women dying at 5 years
varied between the groups - being lowest in DEPCAT 3 (18.3%) and highest in
DEPCAT 6 (38.5%). Since the groups are graded progressively according to SES, it
was appropriate to apply x2 analysis for trend to the data. This produced a x2 value
of 4.96 and a significant p value of 0.026. Despite the p value being significant, it
should be noted that there was not a simple increase in survival figures progressively
with socioeconomic DEPCAT. However, it should be emphasized that DEPCAT 1,
2, 5, 6 and 7 comprise small numbers and therefore the analyses have been repeated
combining DEPCAT to produce zonal groups with similar numbers of cases. These
results are summarised in Table 8. Results are also presented diagrammatically in
Figure 11. Chi-squared analysis for trend showed a statistically significant difference
between groups (x2 = 6.33; p=0.011). Patients from lower SES zonal groups have
poorer survival rates than the most affluent at 5 years. However the percentage of
patients surviving did not increase in a simple progression - in that zone B had the
highest survival and zone D the lowest survival. Indeed, if individual zones are
compared, B versus C and B versus D are significant (p values respectively p=0.05,
p=0.015) (Table 9).
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Table 7: survival at 5 years in SES DEPCAT
DEPCAT score 1 2 3 4 5 6 7 Total
































Total 52 82 126 136 76 13 17 502
Figure 10: percentage of dead patient at 5 years in DEPCAT, p = 0.026
1 2 3 4 5 6 7
□ dead at 5 years □ alive at 5 years
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Table 8: survival at 5 years in SES zones, p = 0.011
Zones A B C D TOTAL
Dead at 5 29 23 40 35 127
years 21.6% 18.3% 29.4% 33% 25.3%
Alive at 5 105 103 96 71 375
years 78.3% 81.7% 70.6% 67% 74.7%
Total 134 126 136 106 502











A B C 0
□ Dead at 5 years a Alive at 5 years
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Table 9: p values of zones compared separately at 5 years survival (NS: not
significant) chi 2 (vertical comparisons) and p values (horizontal comparisons).
A B C D
A NS NS NS
B 0.25 0.041 0.012
C 0.55 0.66 NS
D 0.093 0.65 0.31
B - alive or dead at 10 years
Of the total 502 patients, 72 cases were recruited between 1991 and 1993 so that in
2001 when the analyses were performed they had not completed a 10 year follow-up
period. This leaves a database of 430 patients in whom outcome at 10 years was
known. The number of patients dead at 10 years was 164 (38.1%). The survival
figures at 10 years subdivided according to socioeconomic status are summarised in
Table 10 and shown diagrammatically in Figure 12. Since the DEPCAT are graded
progressively according to SES it was appropriate to apply x2 analysis for trend to
the data. This produced a x2 value of 1.77 and a p value of 0.18. The difference
therefore did not reach significance. As with 5 year survival, the analyses have been
repeated combining zones to produce groups with similar numbers of cases. These
results are summarised in Table 11. Results are also presented diagrammatically in
Figure 13. Chi-squared analysis for trend showed that the difference between zonal
groups did not reach statistical significance (x2=3.938, p=0.0608). However, there was
a progressive increase in mortality with increasing social deprivation. Individual
group comparisons showed no significant differences (Table 12). Indeed, if
individual zones are compared, A versus B, A versus C, A versus D, B versus C and
B versus D, and C versus D are not significant (p values respectively p=0.99, p=0.95,
p=0.12, p=0.43, p=0.12 and p=0.51).
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Table 10: survival for 10 years in different SES DEPCAT
DEPCAT 1 2 3 4 5 6 7 TOTAL
Dead at 17 21 36 46 36 4 4 164
10 yrs 36.1% 32.3% 33.9% 40% 49.3% 40% 28.6% 38.1%
Survived 30 44 70 69 37 6 10 266
at 10 yrs 63.9 67.8% 66% 60% 49.7% 60% 71.4% 61.9%
Total 47 65 106 115 73 10 14 430
Figure 12: survival and dead at 10 years in SES DEPCAT, p = 0.18
1 2 3 4 5 6 7
□ dead at 10 years m survived at 10 years
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Table 11: survival for 10 years in different SES zones
ZONES A B C D
Dead at 38 36 46 44
10 years 33.9% 33.9% 40.0% 45.3%
Alive at 74 70 69 53
10 years 66.1% 66.1% 60% 54.7%
TOTAL 112 106 115 97
Figure 13: survival for 10 years in different SES zones, p = 0.06
A B C D
□ dead at 10 yrs □ survived at 10 yrs
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Table 12: p values of new zones compared separately at 10 years survival, chi
square (vertical comparisons) and p values (horizontal comparisons).
A B C D
A 0.99 0.95 0.12
B 2.75 0.43 0.12
C 0.0036 0.622 0.51
D 2.39 2.29 0.419
C - Kaplan-Meier plots
The numbers in socioeconomic DEPCAT 1, 2, 5, 6 and 7 are not sufficiently large to
perform meaningful analyses by Kaplan-Meier plot. Therefore these analyses have
been restricted to zonal groups. The Kaplan-Meier plot for total patient group overall
survival, subdivided according to zones, is illustrated in Figure 14. It can be seen
that there was a progressive decrease in survival rate as socioeconomic status
decreased. The differences between the curves were statistically significant (p<0.02).
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Figure 14: Socioeconomic status for total patient group and survival in zones
66 100 133
Months of follow up
Green = zone A
Grey = zone B
Yellow = zone C




A - disease-free or recurrent at 5 years
The number of patients recurring at 5 years was 129 (25.7%). The cases subdivided
according to socioeconomic status are summarised in Table 13 and shown
diagrammatically in Figure 15. The percentage of women recurring at 5 years varied
between the DEPCAT groups being lowest in DEPCAT 2 (18.3%) and highest in
DEPCAT 5 (32.9%). Since the groups are graded progressively according to SES, chi-
squared analysis for trend was applied to the data. This produced a x2 value of 2.090
and a p value of 0.1483. It should be noted that despite a lack of significance, there
was a trend for recurrence rates to increase with decreasing affluence. However, it
should be emphasized that DEPCAT 1, 2, 5, 6 and 7 comprise small numbers and
therefore the analyses have been repeated combining zones to produce groups with
similar numbers of cases. These results are summarised in Table 14 and also
presented diagrammatically in Figure 16. Chi-squared analysis for trend did not
reach statistical significance (x2= 3.139; p = 0.0764). However, the percentage of
patients recurring did tend to increase with increasing social deprivation; zone D had
the highest recurrence and zone A the lowest recurrence. Individual zones are
compared versus each other (Table 15).
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Table 13: recurrence rate up to 5 years in SES DEPCAT
DEPCAT score 1 2 3 4 5 6 7 TOTAL
Recurrence 12 15 34 35 25 4 4 129
at 5 years 23% 18.3% 27% 25.7% 33% 30.8% 23.5% 25.7%
No recurrence 40 67 92 101 51 9 13 373
at 5 years 77% 81.7% 73% 74% 67% 69% 76.4% 74.3%
Total 52 82 126 136 76 13 17 502
Figure 15: recurrence rate at 5 years in SES DEPCAT, p = 0.1483
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Table 14: recurrence rate up to 5 years in SES zonal groups
ZONES A B C D TOTAL
Recurrence 27 34 35 33 129
at 5 years 20% 27% 25.7% 31% 25.7%
No 107 92 101 73 373
recurrence 80% 73% 74.2% 68.8% 74.3%
at 5 years
TOTAL 134 126 136 106 502











□ recurrence at 5 years □ no recurrence
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Table 15: p values of new zones at 5 years recurrence, chi square (vertical
comparisons) and p values (horizontal comparisons)
A B C D
A 0.042 0.066 0.0085
B 4.111 0.092 0.58
C 3.380 0.0079
D 6.931 0.301 0.612
B - disease-free or recurrent at 10 years
Of the total 502 patients, 72 cases were recruited between 1991 and 1993 so that in
2001 when the analyses were performed they had not completed a 10 year follow-up
period. This leaves a database of 430 patients in whom outcome at 10 years was
known. The number of patients who recurred at 10 years was 204 (47.4%). The
recurrence figures at 10 years subdivided according to socioeconomic status are
summarised in Table 16 and shown diagrammatically in Figure 17. The percentage
of women with recurrence at 10 years varied between the groups being highest in
DEPCAT 5 (56.1%) and lowest in DEPCAT 2 (40%). Since the groups are graded
progressively according to SES, chi-squared analysis for trend was applied to the
data. This produced a x2 value of 3.7 and a p value of 0.053. The difference therefore
did not reach significance although there was a trend for increasing recurrence in less
socially affluent DEPCAT groups. DEPCAT 1, 2, 5, 6 and 7 comprise small numbers
and therefore the analyses have been repeated combining zones to produce groups
with similar numbers of cases. These results are summarised in Table 17. Results are
also presented diagrammatically in Figure 18. Chi-squared analysis for trend
showed that the difference between zonal groups was statistical significant (x2=4.6,
p=0.03) and there was a progressive increase in recurrence with increasing social
deprivation. Individual group comparisons versus A, B, C and D showed no
significant differences (Table 18).
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Table 16: recurrence rate up to 10 years in SES DEPCAT scores
DEPCAT 1 2 3 4 5 6 7 Total
Recurrence at 19 26 49 57 41 5 7 204
10 years 40.4% 40% 46.2% 49.5% 56.1% 50% 50% 47.4%
No 28 39 57 58 32 5 7 226
recurrence at 59.6% 60% 43.8% 50.5% 45.9% 50% 50% 52.6%
10 years
Total 47 65 106 115 73 10 14 430
Figure 17: recurrence at 10 years in SES DEPCAT, p = 0.053
1 2 3 4 5 6 7
□ RECUR AT 10 YRS ■ NO RECUR
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Table 17: recurrence at 10 years in SES zonal groups
zones A B C D TOTAL
Recurrence at 45 49 57 53 204
10 years 40.1% 46.2% 49.5% 54.6% 47.4%
No 67 57 58 44 226
recurrence at 59.9% 53.8% 50.5% 45.4% 52.6%
10 years
total 112 106 115 97 430
Figure 18: recurrence and disease-free at 10 years in zones, p = 0.03
A B C D
□ RECUR AT 10 YRS a NO RECUR
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Table 18: p values of zones versus 10 years recurrence, chi square (vertical
comparisons) and p values (horizontal comparisons) (NS not significant)
A B C D
A NS NS NS
B 0.58 NS NS
C 0.18 0.13. NS
D 1.31 1.11 0.36
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C - Kaplan-Meier plots
Because of small number in some DEPCAT categories, Kaplan-Meier analyses have
been restricted to zonal groups. The plot for overall recurrence, subdivided
according to zones, is illustrated in Figure 19. Whilst the differences between the
curves were not statistically significant (p=0.277), it was notable that the most affluent
zone appeared to have the best disease-free outcome.
Figure 19: Socioeconomic status and overall recurrence in zones
1.1
1.0
Green = zone A
ql Grey = zone B
.5 Yellow = zone C
.4 Red = zone D
0 33 66 100 133 166 200
Months of follow up
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3.3.4 Correlation of Socioeconomic Status with Established Prognostic
Factors
Lymph nodes
Lymph node status was available in 448 cases. Fifty-four patients did not have their
axillary node assessed due to the fact that they were very old and not fit for surgery -
their tumours were strongly ER positive and they were treated only with hormonal
therapy. Of these patients, 222 (49.5%) were lymph node positive. The incidence of
lymph node positivity in each of the socioeconomic zones is presented in Table 19.
Within the SES group of patients without axillary assessment, there were patients in
each DEPCAT score but the lowest (7.7%) was in DEPCAT 6, and the highest (23.5%)
in DEPCAT 7 (although this is based on only 1 and 4 cases for each DEPCAT
respectively). The distribution of lymph node involvement is shown
diagrammatically in Figure 20. The % positivity varied between 46.2% (DEPCAT 5)
and 66.4% (DEPCAT 6) in different socioeconomic groups. However there was not a
statistically significant trend between positivity and socioeconomic DEPCAT (x2 for
trend 0.02, p=0.881).
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Table 19: SES DEPCAT and nodes status
DEPCAT TOTAL
score 1 2 3 4 5 6 7
22 37 59 63 35 4 6 226
Node -ve 45.8% 50% 51.7% 51.6% 53.8% 33.4% 46.1% 50.5&
26 37 55 59 30 8 7 222
Node +ve 54.2% 50% 48.3% 48.4% 46.2% 66.6% 53.9% 49.5%
Total 48 74 114 122 65 12 13 448
Figure 20: SES DEPCAT and nodes status, p value is 0.88
1 2 3 4 5 6 7
□ nodes -ve □ nodes +ve
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A similar analysis was performed for zonal groups and the data are presented in
Table 20 and Figure 21. The % positivity was similar in each group and there was
not a statistically significant trend between LN positivity and zonal groups (x2 trend
0.077, p=0.78).
The difference between the p values in the groups (A, B, C and D) where comparison
is shown in summary between all groups versus each other (Table 21).
Table 20: SES new zones and node status
zone A B C D TOTAL
Node 59 59 63 45 226
-ve 48.3% 51.7% 51.7% 50% 50.5%
Node 63 55 59 45 222
+ve 51.7% 48.3% 48.3% 50% 49.5%
Figure 21: chi squared value, p = 0.78
52 -
51 -
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Table 21: p values of zones versus lymph nodes status, chi square (vertical
comparisons) and p values (horizontal comparisons)
A B C D
A 0.69 0.70 0.92
B 0.152 0.98 0.91
C 0.146 0.0003. 0.92
D 0.0094 0.0116 0.00941
Oestrogen receptor
Oestrogen receptor status was available in all cases, 326 patients (64.9%) were ER
positive. The incidence of positivity in each of the socioeconomic DEPCAT is
presented in Table 22 and shown diagrammatically in Figure 22. The % positivity
varied between 55.3 (DEPCAT 5) and 76.9% (DEPCAT 6) in different socioeconomic
groups. However there was not a statistically significant difference between
positivity and socioeconomic DEPCAT (x2 for trend 6.745, p=0.3367).
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Table 22: SES DEPCAT and ER status
DEPCAT
score

































Total 52 82 126 136 76 13 17 502
Figure 22: SES DEPCAT and ER status, P value is 0.33
1 2 3 4 5 6 7
□ ER -ve □ ER +ve
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A similar analysis was performed for zonal groups and the data are presented in
Table 23 and Figure 23. The % negativity varied from 29.4% to 41.5% (B and D
respectively) and there was not a statistically significant trend between ER positivity
on zonal groups (y2 trend 3.819, p=0.1728).
Table 23: SES zonal group and ER status
ZONE A B C D TOTAL
ER -VE 46 37 49 44 176
34.3% 29.4% 36% 41.5% 35.1%
ER +VE 88 89 87 62 326
65.7% 70.6% 64% 58.5% 64.9%
Total 134 126 136 106 502










A B C D
□ ER -ve ■ ER +ve
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The difference between the groups (A, B, C and D) versus each other is shown for
comparison in Table 24.
Table 24: p values of zones versus ER status, chi square (vertical comparisons)
and p values (horizontal comparisons)
A B C D
A 0.27 0.86 0.31
B 1.203 0.35 0.072
C 0.0272 0.860. 0.46
D 1.014 3.221 0.542
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Menopausal status
Menopausal status was available in all cases. There were 199 premenopausal and 303
postmenopausal patients. The menopausal status in each of the socioeconomic
DEPCAT is presented in Table 25 and shown diagrammatically in Figure 24. The %
premenopausal varied between 43.4% (DEPCAT 5) and 30.8% (DEPCAT 6) in
different socioeconomic groups. However there was not a statistically significant
difference between menopausal status and socioeconomic DEPCAT; y2 for trend
1.124, p =0.4899.
Table 25: SES DEPCAT and menopausal status
DEPCAT 1 2 3 4 5 6 7 TOTAL
score
PRE 22 29 56 51 33 4 4 199
42.30% 35.40% 44.40% 37.50% 43.40% 30.80% 23.50% 39.60%
POST 30 53 70 85 43 9 13 303
57.70% 64.60% 55.60% 62.50% 56.60% 69.20% 76.50% 60.40%
Total 52 82 126 136 76 13 17 502




1 2 3 4 5 6 7
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A similar analysis was performed for zonal groups and the data are presented in
Table 26 and Figure 25. The % premenopausal varied from 37.5% to 44.4% (C and B
respectively) and there was not a statistically significant trend between menopausal
status on zonal groups; x2for trend 1.657, p= 0.8135 (Table 26).
Table 26: SES zonal groups and menopausal status
Zones A B C D TOTAL
PRE 51 56 51 41 199
38.1% 44.4% 37.5% 38.7% 39.60%
POST 83 70 85 65 303
61.9% 55.6% 62.5% 61.3% 60.40%
Total 134 126 136 106 502
Figure 25: SES zonal groups and menopausal status, p = 0.8135
A B C D
□ PRE hPOST
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The difference between p values of the groups (A, B, C and D) is shown for
comparison in Table 27.
Table 27: p values of zonal groups versus menopausal status, chi square (vertical
comparisons) and p values (horizontal comparisons)
A B C D
A 0.357 0.924 0.921
B 0.845 0.275 0.451
C 0.00899 1.189. 0.950
D 0.0096 0.567 0.00292
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T stage
The staging used is the TNM classification, UICC International Union Against
Cancer; the number of patients with DCIS was 13 and they were excluded from the
study. Because the number of patients in T3 and T4 were low they were included
together as T3/4. There were 85 patients in Tl, 359 in T2 and 58 patients in T3/4 (54 in
T3 and 4 in 4).
Each of the socioeconomic DEPCAT is presented in Table 28 and shown
diagrammatically in Figure 26.
Table 28: SES DEPCAT and T stage tumours
DEPCAT
score

















































Total 52 82 126 136 76 13 17 502
Figure 26: SES DEPCAT scores and tumour staging, p = 0.296
1 2 3 4 5 6 7
□ T1 ■ T2 nT3
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The % of T stage varied between 23.1%% (DEPCAT 6) and 12.7% (DEPCAT 3) for T1
in different socioeconomic DEPCAT, 82.4 % (DEPCAT 7) and 61.8% (DEPCAT 5) for
T2 and 21.1 % (DEPCAT 5), and 0 (DEPCAT 7) for T3. However there was not a
statistically significant difference between T stage and socioeconomic and DEPCAT
scores (x2 for trend 14.00, p = 0.296). Similar analysis was performed for zonal groups
and again it was not significant statistically (x2 value is 6.214, p=0.400). These data
are presented in Table 29 and Figure 27.
Table 29: SES zonal group and T staging tumour size
ZONE A B C D TOTAL
T1 27 16 23 19 85
20.1% 12.7% 16.9% 17.9% 16.9%
T2 96 96 97 70 359
71.6% 76.2% 71.3% 66% 71.5%
T3/4 11 14 16 17 58
8.2% 11.1% 11.8% 16% 11.6%
Total 134 126 136 106 502
Figure 27: SES zonal groups and tumour staging, p = 0.400
A B C D
□ T1 a T2 □ T3
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The difference between the p values between the groups (A, B, C and D) is shown for
comparison (Table 30).
Table 30: p values of zones versus T stage, chi square (vertical comparisons) and p
values (horizontal comparisons)
A B C D
A 0.099 0.289 0.159
B 2.711 0.573 0.966
C 1.121 0.3161. 0.650
D 1.976 0.00181 0.2052
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3.3.5 Correlation of established prognostic factors with outcome
Lymph node involvement is a very well documented prognostic factor for survival;
more involved lymph nodes, worse will be the survival.
Lymph node status
Of the 502 patients, 448 cases had lymph node status documented 222 (49.5%) were
lymph node positive.
5 year survival
Of the 222 lymph positive cases, 68 (30.6%) had died by 5 years. The number of
deaths in the lymph node negatives was 34 of 226 (15.0%), an incidence half that of
the lymph node positive group. By chi-squared analysis the difference in death rate
between LN-ve and LN+ve patients was highly significant (x2 value is 14.60,
p=0.0001).
Alive Dead
LN-ve 192 34 (15.0%)
LN+ve 154 68 (30.6%)
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10 year survival
Of the total 502 patients, 72 cases were recruited between 1991 and 1993 so that in
2001 when the analyses were performed they had not completed a 10 year follow-up
period. This leaves a database of 430 patients in whom outcome at 10 years was
known. Of these patients, 384 cases had lymph node status documented. Of these,
193 (48.9%) were lymph node positive. Of the lymph positive cases, 89 (46.1%) had
died by 10 years. The number of deaths in the lymph node negatives was 48 of 191
(25.1%). By chi-squared analysis the difference in death rate between LN-ve and
LN+ve patients was highly significant (x2=17.52, p=0.0001).
Alive Dead
LN-ve 143 48 (25.1%)




The Kaplan-Meier plot for overall survival, subdivided according to lymph node
involvement, is illustrated in Figure 28. It can be seen that there was a progressive
fall in survival rate between negative and positive lymph node involvement. The
differences between the curves were statistically significant (p< 0.0001).
Figure 28





All of the 502 patients had their ER status documented (176 (35.1%) were ER
negative).
5 year survival
Of the 176 ER negative cases, 68 (38.6%) had died by 5 years. The number of deaths
in the ER positive was 55 of 271 (16.8%), an incidence almost double that of the ER
negative group. By chi-squared analysis the difference in death rate between ER-ve
and ER+ve patients was highly significant (x2=28.1, p=0.001).
Alive Dead
ER-ve 108 68 (38.6%)




As mentioned above, out of the total 502 patients, 72 cases were recruited between
1991 and 1993 so that in 2001 when the analyses were performed they had not
completed a 10 year follow-up period. This leaves a database of 430 patients in
whom outcome at 10 years was known. Of these, 157 (35.1%) were ER negative. Of
the ER negative cases, 69 of 157 (43.9%) had died by 10 years. The number of deaths
in ER positive was 95 of 273 (34.8%). By chi-squared analysis the difference in death
rate between ER-ve and ER+ve patients was not significant (x2=3.16, p=0.076).
Alive Dead
ER-ve 88 69 (43.9%)




The Kaplan-Meier plot for overall survival, subdivided according to ER status, is
illustrated in Figure 29. It can be seen that there is no change in survival rate with ER
status. The differences between the curves were statistically not significant (p<0.211).
Figure 29
Zones - Survival by ER
yrs
STRATA: ■■■■■■» erg Neg/Poor ergnRich
T stage
All of the 502 patients had their T stage documented (85 (16.9%) were Tl, 359 (71.5%)
T2, and 58 (11.6%) were T3/4).
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5 year survival
Of the 85 T1 cases, 22 (25.8%) had died by 5 years. The number of deaths in the T2
was 83 of 359 (23.2%), and 18 (31%) of 58 in T3/4. By chi-squared analysis the
difference in death rate between Tl, T2 and T3/4 patients was not significant (x2=0.26,
p=0.609).
Alive Dead
Tl 63 22 (25.8%)
T2 276 83 (23.2%)
T3/4 40 18 (31.0%)
(X2=0.26, p=0.609)
10 year survival
Of the total 502 patients, 72 cases were recruited between 1991 and 1993 so that in
2001 when the analyses were performed they had not completed a 10 year follow-up
period. This leaves a database of 430 patients in whom outcome at 10 years was
known. Of these, 18 (25%) were Tl. Of the T2 cases, 121 of 306 (39.5%) and 25 cases
from T3/4 of 52 cases had died by 10 years. By chi-squared analysis the difference in
death rate between Tl, T2 and T3/4 patients was highly significant (x2=7.37, p=0.007).
Alive Dead
Tl 54 18 (25.0%)
T2 185 121 (39.5%)




The Kaplan-Meier plot for overall survival, subdivided according to T stage, shows a
progressive decrease in survival rate as the T stage increases. The differences
between the curves were statistically significant (p<0.0061) (Figure 30).
Figure 30: survival by T stage, p = 0.0061
Survival by T stage
yrs
STRATA: TS-I TS-2 TS=3/4
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Menopausal status
The menopausal status was classified in all women as either premenopausal (regular
menstrual periods) or postmenopausal (at least 3 years beyond their last menstrual
period). All of the 502 patients had their menopausal status documented (199
(39.6%) were premenopausal status and 303 (60.4%) postmenopausal).
5 year survival
Of the 199 premenopausal cases, 48 (24.1%) had died by 5 years. The number of
deaths in the postmenopausal was 75 (24.7%) of 303, an incidence almost the same in
each group. By chi-squared analysis the difference in death rate between
menopausal status patients was insignificant (x2=0.0003, p=0.956).
Alive Dead
Premenopausal 151 48 (24.1%)




Of the total 502 patients, 72 cases were recruited between 1991 and 1993 so that in
2001 when the analyses were performed they had not completed a 10 year follow-up
period. This leaves a database of 430 patients in whom outcome at 10 years was
known. Of these, 60 (30.1%) were premenopausal. Of the postmenopausal cases, 104
of 303 (34.6%) had died by 10 years. By chi-squared analysis the difference in death
rate between menopausal status patients was insignificant (x2=1.07 p=0.30).
Alive Dead
Premenopausal 112 60 (30.1%)




The Kaplan-Meier plot for overall survival, subdivided according to menopausal
status is illustrated in Figure 31. It can be seen that there is no change in survival rate
with menopausal status. The differences between the curves were statistically not
significant (p<0.1834).
Figure 31: survival by menopausal status, p< 0.1834






As was mentioned above in Survival, not all patients had their axillary dissection
surgery. As a result of this, out of the 502 patients, 448 cases had lymph node
documented (222 (49.5%) were lymph node positive).
5 year recurrence
The number of recurrences in the lymph node negatives was 50 (22.1%) of 226, and of
the 222 lymph positive 90 (40.5%) had recurred cases by 5 years. The incidence of
recurrence almost doubled in lymph node positive group. By chi-squared analysis
the difference in recurrence rate between LN-ve and LN+ve patients was highly
significant (x2=16.83, p=0.0001).
DF REC
LN-ve 176 50 (22.1%)




Of the 193 lymph positive cases, 106 (54.9%) had recurred by 10 years. The number
of recurrences in the lymph node negative group was of 70 of 191 cases (36.6%). By
chi-squared analysis the difference in recurrence rate between LN-ve and LN+ve
patients was highly significant (x2=12.18, p=0.0005).
DF REC
LN-ve 121 70 (36.6%)




The Kaplan-Meier plot for recurrence, subdivided according to lymph node
involvement, is illustrated in Figure 32. It can be seen that there was a progressive
increase in recurrence rate as lymph node involvement increases. The differences
between the curves were statistically significant (p<0.0001).
Figure 32: Kaplan-Meier p of <0.0001











All 502 patients had their ER status documented. 176 (35.1%) were ER negative and
326 (64.9%) were ER positive.
5 year recurrence
The number of recurrences in the ER negatives was 76 (43.1%) of 176, and of the 326
ER positive 86 (26.3%) had recurred cases by 5 years. The incidence of recurrence is
higher in ER negative group. By chi-squared analysis the difference in recurrence
rate between ER-ve and ER+ve patients was highly significant (x2=14.00, p=0. 0002).
DF REC
ER-ve 100 76(43.1%)
ER+ve 240 86 (26.3%)
(X2=14.00, p=0. 0002)
10 years recurrence
Of the 273 ER positive cases, 129 (47.2%) had recurred by 10 years. The number of
recurrences in the ER negative group was 75 of 157 cases (47.7%). By chi-squared
analysis the difference in recurrence rate between ER-ve and ER+ve patients is not
significant (x2=1.066, p= 0.99).
DF REC
ER-ve 82 75 (47.7%)




The Kaplan-Meier plot for recurrence, subdivided according to ER status, is
illustrated in Figure 33. It can be seen that there is change in recurrence rate with ER
status. The differences between the curves were statistically significant (p<0.010).
Figure 33: Kaplan-Meier p value of 0.010
0.25





All of the 502 patients had their T stage documented (85 (16.9%) were Tl, 359 (71.5%)
T2 and 58 (11.6%) were T3/4).
5 year recurrence
129 patients had recurrence at 5 years (25.7%) and 373 were disease free. 24 (28.2%)
of 85 developed recurrence in Tl group, 113 (31.4%) had recurrence at 5 years in T2
group, and 25 (43.1%) in T3/4 group of 58 cases. By chi-squared analysis the
difference in recurrence rate at 5 years between Tl, T2 and T3/4 patients was not
significant (x2=3.05 p=0.08).
DF REC
Tl 61 24 (28.2%)
T2 246 113 (31.4%)




Of the total 502 patients, 72 cases were recruited between 1991 and 1993 so that in
2001 when the analyses were performed they had not completed a 10 year follow-up
period. This leaves a database of 430 patients in whom outcome at 10 years was
known. Of these, 26 (36.1%) had recurrence at 10 years of 72 cases in Tl, 149 (48.6%)
of 306 cases in T2 and 29 (55.7%) of 52 cases in T3/4 had recurrence at 10 years. By
chi-squared analysis the difference in recurrence rate between Tl, T2 and T3/4
patients was highly significant (x2=5.08, p=0.024).
DF REC
Tl 46 26 (36.1%)
T2 157 149 (48.6%)




The Kaplan-Meier plot for recurrence, subdivided according to T stage (Figure 34)
shows a progressive increase in recurrence rate as the T stage increases. The
differences between the curves were statistically significant (p<0.0238).
Figure 34: Kaplan-Meier p value of 0.0238
Recurrence by T stage
Years
— T1 — 12 — T3/4
123
Menopausal status
The menopausal status was classified in all women as either premenopausal (regular
menstrual periods), postmenopausal (at least 3 years beyond their last menstrual
period [148], All of the 502 patients had their menopausal status documented (199
(39.6%) were classified as premenopausal and 303 (60.4%) postmenopausal).
5 year recurrence
Of the 199 premenopausal cases, 69 (34.6%) had recurrence at 5 years. The number
of recurrence in the postmenopausal was 93 (30.7%) of 303, an incidence which is
almost the same in both groups. By chi-squared analysis the difference in recurrence
rate between menopausal status patients was insignificant (x2=0.70, p=0.40).
DF REC
Premenopausal 130 69 (34.6%)




As mentioned earlier with regards to survival at 10 years, not all patients had 10 year
follow-up. As a result of this, out of the total 502 patients, 72 cases did not have 10
years follow-up for recurrence. This leaves a database of 430 patients in whom
recurrence at 10 years was known. Of these, 82 (47.6%) were premenopausal. Of the
postmenopausal cases, 122 of 258 (48.2%) had recurrence by 10 years. By chi-squared
analysis the difference in death rate between menopausal status patients was
insignificant (y2=20.1, p=0.93).
DF REC
Premenopausal 90 82 (47.6%)




The Kaplan-Meier plot for recurrence, subdivided according to menopausal status is
illustrated in Figure 35. It can be seen that there is no change in survival rate with
menopausal status. The differences between the curves were statistically not
significant (p<0.18).
Figure 35: Kaplan-Meier p of 0.18








3.3.7 Multivariate analysis (Proportional hazards analysis)
Multivariate analyses were performed including the following possible
prognostic variables Year treated, Age, Menopausal status, T stage ,
ER(status), Clinical size, lymph nodes status (Number of +ve nodes), and
Zone (socio-economic status).
SURVIVAL
Only 441 patients out of 502 have information on all these variables for survival and
can be included in the analysis.
Prognostic variables independently significant for survival are shown in Table 31;
variables not significant, ie socio-economic status, were not included.
Table 31: Survivals and variable with significant p values and hazards
Variable P Hazard
Number of +ve nodes <0.0001 Increasing
Size <0.0001 Increasing




Only 441 patients out of 502 were included in the analysis, the same 8 variables as
above were considered as possible prognostic variables for recurrence, again socio¬
economic status was not significant.
Table 32: Recurrence and variable with significant p values and hazards
Variable P Hazard
Number of +ve nodes <0.0001 Increasing
Size 0.0009 Increasing
Age 0.0046 Decreasing
Year treated 0.0225 Increasing
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3.4 Discussion
The outcome of breast cancer is variable even in patients presenting with same stage
of disease. Many factors may account for this and parameters such as tumour size,
lymph node involvement, ER receptors status and menopausal status have been
implicated. Despite this it is clear that there are other variables which can be
influential. These include the SES and background of the patient. Although SES has
been extensively studied with regard to risk of breast cancer factors (and there is a
consensus that women from affluent backgrounds are at increased risk)
investigations focusing on the outcome of established breast cancer are less frequent.
Furthermore, not all studies have detected significant relationship, and those that
had usually have found that social deprivation is associated with worse outcome (the
reverse of the association with risk).
There are several advantages in looking at the potential relationship between SES
and breast cancer outcome in women living in the southeast of Scotland. Thus, most
of the women diagnosed with breast cancer are referred to the Edinburgh Breast
Unit. This Unit represents the major referral centre for the southeast of Scotland and
sees over 90% of patients from this area. These patients are routinely and rigorously
followed up and given standardized treatment according to Unit policy, regardless
of the socioeconomic background.
This geographic population of the southeast of Scotland is relatively stable and can
be stratified into different socioeconomic groups according to postcode of residence.
Carstairs Index has been used in several successful studies in Scotland and
worldwide.
The patient population investigated in this study was referred to the Edinburgh
Breast Unit between 1985 and 1993 so that when analyses were performed all had a
follow-up of at least 8 years. Cases were selected on the basis that tumour material
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from the patients had been stored in liquid nitrogen for investigation within the
scope of this present study. As a consequence, the series constituted only a minority
of the breast cancer cases diagnosed in southeast Scotland. However, there are no
reasons to believe that the cases studied were not representative of the overall
population and have normal demographic in terms of clinical outcome.
To confirm that this was indeed the case, correlations have been established between
prognostic factors and outcome. Thus in the present study population established
poor prognosis factors, such as increasing T stage and lymph node involvement,
were highly significantly associated with early recurrence and death from breast
cancer as reported previously [66, 229].
Similarly, increasing T stage was generally associated with poor outcome being
significantly (and inversely) related to overall survival and recurrence (positively) by
Kaplan-Meier analysis.
Positive ER status is generally thought to have favourable prognostic factors,
although it does appear as significant in some studies. This would be consistent with
the findings in the present study in which ER positive tumours were significantly
less likely to recur early (Kaplan-Meier at 5 year analysis, but not 10 years); ER status
and survival at 5 years was significant at 5 years but was not significant at 10 years
and for Kaplan-Meier. In terms of menopausal status, no significant association was
found with outcome, recurrence or survival, which is again compatible with
published literature.
The major analyses in the study were the correlations between SES and long-term
clinical outcome. Associations have been made with death from breast cancer and
recurrence of breast cancer. For each of these parameters multiple statistical testing
has been performed with regards to time of follow-up (at 5 years, 10 years and over
the total follow up period) and category of socioeconomic grouping (DEPCAT and
zones).
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Whist this has advantages in providing different perspective, it also has the
disadvantage in that multiple testing may give rise to spurious significant results and
inconsistence. In drawing conclusions, emphasis should be given to consistency of
associations and greater reliance attached to Kaplan-Meier (which utilises total
follow up data) and zones (which contain greater number of cases).
In term of survival, findings generally indicated that increased social deprivation
was associated with adverse outcome. This was evident in the 5 year figures and
also Kaplan-Meier analysis of total analysis (the trend was similar at 10 years but did
not reach significance, presumably because of the lower number of events). These
results would be compatible with other studies, most notably in the west of Scotland.
With regard to recurrence rates, similar trends of poorer outcome for less affluent
women were apparent. However, with the exception of recurrence rates for zonal
analysis at 10 years, none of these reached statistical significance, despite the
increased number of events compared with survival data. It can only be a matter of
hypothesis as to why associations are stronger between SES and survival compared
with recurrence.
In an effort to determine factors which might have contributed to a poorer outcome
of socially deprived women, the relationship between SES and known prognostic
factors was also examined.
No significant relationship was found between LN status, T stage status, ER status
and menopausal status. It is therefore unlikely that these parameters contributed to
the adverse survival data of the socioeconomically deprived. It is important to
compare these results with previously published data. Whilst there are reports that
socially deprived women present with more advance disease in terms of LN
involvement and larger tumours, the literature equally contains publications which
show no association.
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Menopausal status was not statistically significant between premenopausal and
socioeconomic zone. Other studies looked at the relationship between SES and age,
which suggest younger women have poorer survival. In younger women (30-64
years), the survival gradient by deprivation category cannot be explained by these
prognostic factors [198].
The present study did not show an association between tumour ER status and
patients' SES, although several studies (including one in the west of Scotland) have
suggested that patients from socially deprived areas are more likely to have ER
negative tumours and because of this will have a poorer prognosis [191].
Whilst the lack of correlation between SES and tumour ER, stage and treatment in
the present study mean that the latter parameters individually cannot account for the
relationship between SES and long-term survival, in multivariate analysis,
prognostic variables such as lymph node status, ER status, age and clinical tumour
size were the only independently significant for survival and recurrence. It seems





Whilst the investigation in Chapter 2 on the location of the primary tumour within
the breast in two groups of patients diagnosed 40 years apart and Chapter 3 on the
effects of socioeconomic status on prognostic factors and outcome of patients with
breast cancer may appear to be separate, and indeed can stand alone, they have in
common (i) the need for a comprehensive and well-validated database of patients
presenting with breast cancer and (ii) that the cases of breast cancer are derived from
a well-defined and stable population. The cases of breast cancer diagnosed in the
southeast of Scotland and/or referred to the Edinburgh Breast Unit fulfil these
criteria.
The studies linking social history to either presentation of breast cancers or the
impact of social economic status on clinical outcome have made use of data collected
on breast cancer in the Edinburgh Breast Unit which covers a vast area of southeast
Scotland, and offers good and equal treatment to all patients regardless of their social
background. Access to the records and files of homogenous patients relating to
breast cancer and its' outcome, and whether the disease has changed in its
appearance over time, made these studies possible.
By comparing records from 1957-1959 with those from 1997-1999 it was possible to
demonstrate that the location of breast cancer within the breast has changed with
time. The most significant difference in the cancers between the cohorts was the
decrease in tumour size. Similar changes over time have been previously reported.
This is likely to be in large part because of better education, with increasing breast
awareness and the introduction of the screening programme in Edinburgh in 1991.
The present study has confirmed previously reported findings that the distribution
of breast cancer is not even throughout the breast but is higher in the upper outer
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quadrant (UOQ). There was an increase in the likelihood of finding a cancer in the
lower outer quadrant (LOQ).
Although this has been formally published in only one study in the UK in which
incidence of breast cancer in the UOQ rose disproportionately from 38.3% in 1980 to
54.7% in 2001 [138], and is true for countries as diverse as India [125], the West Indies
[126] and Italy [127], and irrespective of race from the same country [128], it is
interesting to note that the reported incidence of breast cancer in the UOQ appears to
rise disproportionately with year of publication [134-136] which would be in keeping
with the present observations.
In 1926, 30.9% of breast cancer was reported to be in the UOQ [133], but reports
between the years 1947-1967 suggested that the proportion of breast cancer in the
UOQ was 43-48%. A study in 1994, reported 60.7% of breast cancers in the UOQ
[127],
This change in location is a reflection of other changes over time in the incidence and
behaviour of breast cancer. Thus, the overall incidence of breast cancer is rising in
Britain [163,164] and indeed all over the world [15, 230, 231]. Also the staging has
changed, more early breast cancer being seen compared with the past. This might be
due to the efficiency of the screening mammogram.
The histology of breast cancer has also changed, as has been mentioned in Chapter 2.
Ductal carcinoma incidence rates remained essentially constant, while lobular
carcinoma rates increased steadily [163, 164].
Even when looking at the laterality of breast cancer incidence, there is change in the
laterality. Earlier studies showed that the left breast is more prone to development of
cancer than the right breast, in both female and male [124-126,140, 142, 160, 161]. In
a more recent study, the numbers of right-sided and left-sided breast cancer
incidence were roughly equal [161] and the present study showed the laterality of
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incidence is almost identical (no changes between left and right in breast cancer
incidence between the two cohorts).
Although elsewhere breast cancer is rising in women of all socioeconomic status in
Scotland and the deprived-affluent gap remains [180], the exact causes behind these
observations are not fully defined and, indeed, it is likely that the differential effects
may be multifactorial.
There is a long-standing awareness that poverty is associated with general risk of ill-
health and outcome from disease. However, some of the reasons underlying the
phenomenon include lifestyle factors such as diet, stress, reproductive and child-
bearing parity, the use of oral contraceptives, HRT, radiation and environmental
factors, but it cannot be excluded that the increased incidence in more affluent
populations is due to more efficient diagnosis of the disease.
Although social background, lifestyle and environment have changed markedly in
Scotland over the last 40 years, it would appear that there is a consistency with
regard to SES and outcome. The present study confirms the poorer survival of
patients from low SES areas. This was also noted in earlier published reports.
The major conclusions of this study are that:
i) presentation of breast cancer in terms of location within the breast has changed
with time.
ii) despite major changes in lifestyle the outcome of patients from deprived SES is
poorer than in more affluent women. The underlying causes for these
observations are largely undefined but they could provide clues as to the causes
of breast cancer and the changes in detection and natural history of the disease,
and also illustrate the potential of analysing data stored in stable databases from
major referral centres such as the Edinburgh Breast Unit.
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